Capital Equipment Financing and Risk Management in Healthcare Technology Procurement

Ifeoma Okoli[1*], Priscilla Agboada[2], Ann Kinyanjui[3], Abiola Akintobi[4], Omotayo Pedro[5]

[1]General Electric – GE Vernova & Healthcare, Nigeria
[2]Emirates, Dubai, UAE
[3]Hallmark Advertising and Marketing Ltd, Kenya
[4]Moore Bishop & Rooks, Nigeria
[5]McKesson, Vilnius, Lithuania
*Corresponding author: Ifeoma Okoli — Ifeomaokoli47@gmail.com

ABSTRACT

Aim. This article develops an integrative decision framework for capital equipment financing in healthcare technology procurement. It addresses three linked problems that existing treatments handle separately: fragmented measurement across finance, analytics, and risk functions; weak treatment of uncertainty in lifecycle cost and technology obsolescence; and a persistent separation between commercial financing decisions and clinical risk governance.

Materials and methods. A structured narrative synthesis draws on finance, analytics, technology, operations, governance, and sector-specific literature, compared thematically rather than treated as an undifferentiated bundle. Empirical, review, and conceptual sources are admissible because the objective is theory integration rather than pooled effect estimation.

Results. The resulting framework organizes evidence across clinical need, lifecycle cost, financing structure, technology obsolescence, supplier performance, and patient safety. It defines lifecycle clinical and financial value as the focal decision criterion and proposes a sequence of data definition, baseline construction, causal or comparative estimation, risk adjustment, scenario testing, governance review, and post-implementation learning. The analysis shows that isolated efficiency or revenue measures are insufficient because they omit implementation costs, tail losses, customer effects, and timing.

Conclusion. The article contributes a reusable architecture that links economic evaluation with accountable execution, closing the gap between capital appraisal tools built for generic assets and the clinical, regulatory, and supplier-dependent character of healthcare technology. It also specifies research propositions, measurement fields, validation tests, and raeporting practices suitable for empirical testing. No confidential company data are used and no causal claims are made about named employers. Decision quality improves when value, risk, behavior, and control effectiveness are evaluated within one auditable model.

KEYWORDS: healthcare, equipment, procurement, capital, finance, risk, technology, lifecycle
DOI:10.21590/ijhit.spcl.02.02

1. INTRODUCTION

Providers that buy, lease, and maintain clinical technology operate under simultaneous pressure to strengthen capital equipment financing and to safeguard patients, counterparties, regulators, and long-run financial capacity. What makes the management problem hard is that measured outcomes are jointly produced by market conditions, prior relationships, operational execution, technology constraints, and selection effects. Neither a strong reported return nor a low incident rate, taken on its own, demonstrates that incremental value was created or that a control actually works. (Elfenbein & Zenger, 2009; Vesal et al., 2013).

Relevant scholarship sits in several unrelated literatures: corporate finance, marketing science, information systems, operational risk, cybersecurity, and sector-specific regulation. Each supplies usable instruments, yet they disagree about assumptions and about the unit at which phenomena should be measured. Discounted cash flow and capital constraints organize the finance work; prediction, segmentation, and experimentation organize the analytics work; exposure, control effectiveness, and resilience organize the risk work. (Chorn & Carr, 1997; Marianne & Thomas, 2016).

Three questions organize the review. How should a provider weigh purchase against lease, managed service, and performance-based financing? Which risks deserve a place inside lifecycle economic evaluation? And by what route should clinical value and patient safety enter the capital approval decision? Answering them shifts the analysis away from descriptive performance reporting and toward accountable choice. The contribution here is conceptual rather than empirical: it specifies constructs and relationships that later studies can test against transaction, customer, asset, campaign, or control data. (Bambagioni, 2017; Jordan, 2006).

No single model fits every institution, and this article does not pretend otherwise. Regulatory obligations, market maturity, product economics, data availability, and organizational capability all vary. The framework therefore separates invariant design principles from parameters that must be calibrated locally. Invariant principles include a clear counterfactual, a consistent time horizon, full cost allocation, explicit risk adjustment, model validation, and documented decision rights; local parameters include loss severity, discount rate, customer sensitivity, capital charges, and intervention thresholds. (Harrington, 2009; Kiselev & Alexandrovna, 2019).

2. BACKGROUND

2.1 Health technology assessment

Formal appraisal in health technology assessment weighs incremental cash flows against opportunity costs, capital use, and uncertainty. The objective that matters is not volume but durable value remaining after direct cost, indirect cost, expected loss, and the required return have been deducted. (Fiscus, 1999; Gupta, 2000a) (“Comparative Analysis,” 2018; Konstantinos, 2017).

The relationship between clinical need and lifecycle clinical and financial value is a decision pathway, not a correlation. A manager interprets an imperfect signal about clinical need, turns that reading into a specific intervention, and only afterwards absorbs the financial, operational, and clinical consequences of acting. Taking the pathway one step at a time, instead of regressing clinical need straight onto lifecycle clinical and financial value, both limits attribution error and shows where value leaks between the signal observed and the outcome realized. Any credible model consequently records the decision rule, the baseline used for comparison, implementation cost, the horizon considered, the uncertainty band around the estimate, and the way effects are distributed across customers and counterparties. (Bai et al., 2015; Jacques et al., 1995) (Austin & Mitchell, 2008).

The tension between patient safety and clinical need is structural rather than incidental. Resources and attention given to one are largely unavailable to the other, so isolated optimization of either dimension tends to shift cost or risk instead of removing it. Within healthcare technology procurement a favorable reading on patient safety taken by itself says little about total value; the framework proposed here therefore treats patient safety and clinical need as joint constraints and tests their interaction through scenario analysis, control testing, and sensitivity analysis. That keeps short-term accounting gains from concealing later losses, customer harm, compliance expense, or strategic rigidity, and it supports separate reporting of gross benefit, incremental benefit, and risk-adjusted benefit, with confidence intervals that finance, risk, operations, technology, and customer teams can challenge directly. (Aroh et al., 2015; Lee, 2016) (Okafor et al., 2024).

How much value is attributed to patient safety depends substantially on the horizon over which it is measured, because benefits typically front-load while losses, attrition, obsolescence, remediation costs, and regulatory consequences back-load. Discounting expected cash flows over multiple periods, applying scenario-specific probabilities, and pricing management's option value addresses that timing asymmetry directly. It stops an early favorable read on patient safety from dominating the healthcare technology procurement appraisal and instead supports staged commitments with pilot gates, covenant triggers, and defined review points. (Contardi, 2019; Simsir & Altindis, 2019).

Clinical need cannot be measured meaningfully until the unit of analysis has been specified, whether customer, account, transaction, asset, route, service provider, or reporting cycle, because comparisons that quietly mix units produce biased results and weaken causal interpretation. The framework therefore requires every clinical need metric to be tied to an owner, a source system, a refresh frequency, a permissible use, a validation threshold, and an escalation path, so that measurement supports rather than merely describes capital equipment financing decisions in healthcare technology procurement. (Currey et al., 2011; Houria et al., 2016) (Okonkwo et al., 2018).

2.2 Procurement in healthcare organisations

Procurement analytics earns its keep only when observations are converted into decisions and outcomes feed back into learning. Predictive accuracy, on that view, is an intermediate capability rather than the performance measure that matters most. (Mbonu et al., 2020; Oparah et al., 2024; Okonkwo et al., 2021; Falegan & Aniebonam, 2022; Akinlade et al., 2024; Uduokhai et al., 2025; Ashore-Onisemo et al., 2020; Atakpa & Fobellah, 2023a).

Wherever procurement authority is delegated, information asymmetry and conflicting incentives follow. Four devices temper them: clear ownership, independent challenge, audit trails, and explicit escalation rules. (Okonkwo et al., 2023; Abetoh & Atakpa, 2024) (Ruud, 1995).

Markets, customer behavior, threats, regulation, and technology all move. Procurement organizations accordingly need routines for sensing, learning, and reconfiguration rather than a set of assumptions fixed once a year. (Akinlolu et al., 2024) (Altind, 2019).

How well a technology performs depends on its fit with clinical workflow, on user behavior, on data stewardship, and on continued management reinforcement. Deploy without adoption and the expected benefits simply never appear. (Okonkwo et al., 2019).

2.3 Equipment financing and leasing

In practice lifecycle cost and financing structure pull in opposite directions. Tightening one typically displaces cost or risk into the other instead of eliminating it. An equipment program that looks efficient on a lifecycle cost metric alone may be quietly financed by a deterioration in financing structure, and that shift stays invisible unless the two are evaluated together through scenario analysis, control testing, and sensitivity analysis run against a shared baseline. Read this way, short-term accounting gains on either dimension can conceal later losses, customer harm, compliance expense, or strategic rigidity. Decision makers should therefore report gross benefit, incremental benefit, risk-adjusted benefit, and confidence intervals as separate lines rather than as one blended figure, which is what gives finance, risk, operations, technology, and customer teams something concrete to challenge. (Ford et al., 2015; Lakshmi & Sahoo, 2012) ("Frequency Analysis," 2018).

Sound measurement of financing structure begins with fixing the unit of analysis. Customer, account, transaction, asset, route, service provider, and reporting cycle are all legitimate choices, but mixing them across comparisons biases the estimate without anyone noticing and weakens whatever causal claim rests on it. Applied to financing structure, this review gives each metric an owner, a source system, a refresh frequency, a permissible use, a validation threshold, and an escalation path. That turns measurement from an ad hoc dashboard exercise into a repeatable management control capable of supporting capital equipment financing decisions in healthcare technology procurement. (., 2018; Pathirana et al., 2019b) (Okoruwa et al., 2024) (Mueller et al., 2011).

Financing structure and lifecycle clinical and financial value are connected through a chain of managerial choices, not by a direct effect, and collapsing the two into one correlated pair hides more than it shows. Once financing structure is observed, a manager must still decide whether and how to intervene; that intervention, not the raw signal, is what shapes lifecycle clinical and financial value in healthcare technology procurement. Modeling the full pathway of signal, intervention, and consequence keeps the analysis honest about where uncertainty enters and prevents an apparent association between financing structure and lifecycle clinical and financial value from being read as a causal shortcut. The practical implication is a decision record that fixes the baseline, the cost of acting, the horizon over which outcomes are judged, and the distribution of effects across the parties involved. (Grenvik, 2001; Tabarov et al., 2020) (Akin-Oluyomi et al., 2023a; Atakpa et al., 2024a;

Aneke & Adesemoye, 2021; Eboh & Aliliele, 2024; Akinola et al., 2024; Sharon & Rihel, 2026; Unamma & UM-L, 2022; Atakpa et al., 2024b).

Silently switching the unit of analysis is a recurring failure mode in financing structure measurement: a customer-level figure from one period compared against an asset-level figure from the next, biasing the comparison without anyone necessarily noticing. Governance answers this by fixing a single unit for financing structure, whether customer, account, transaction, asset, route, service provider, or reporting cycle, and giving the resulting metric an owner, a source system, a refresh frequency, a permissible use, a validation threshold, and an escalation path. Measurement of financing structure then functions as a repeatable control rather than a one-off dashboard exercise within healthcare technology procurement. (Baku, 2019; Hafez, 2018) (Akinleye, 2023) (Aliliele et al., 2023b).

2.4 Lifecycle and maintenance management

What lifecycle cost contributes economically depends as much on timing as on magnitude. Benefits can appear quickly while losses, attrition, obsolescence, remediation costs, or regulatory consequences emerge only later, so a static point estimate of lifecycle cost flatters the early period and understates the tail. Discounting expected cash flows over several periods, applying scenario-specific probabilities, and pricing the option value management retains corrects for this in healthcare technology procurement: it prevents favorable early indicators from dominating the appraisal of lifecycle cost while still supporting staged commitments, pilot gates, covenant triggers, and review points at which managers can expand, redesign, pause, or exit. (Levaggi & Moretto, 2004; Olaiya, 1999) (Aifuwa et al., 2020) (Oparah et al., 2021; Olodo et al., 2026; Ogbete et al., 2021; Aliliele et al., 2023a; Ekwunife et al., 2024; Nnaji & Akinlolu, 2026; Atakpa & Abolaji, 2020; Atakpa et al., 2023b).

The trade-off between technology obsolescence and supplier performance is real, not merely statistical: gains booked against one are frequently financed by costs displaced onto the other. A framework that scores technology obsolescence in isolation will therefore overstate program value in healthcare technology procurement, because it never observes the offsetting movement in supplier performance. Treating both as joint constraints and testing them together through scenario analysis, control testing, and sensitivity analysis keeps the displacement visible, instead of letting short-term accounting gains conceal later losses, customer harm, compliance expense, or strategic rigidity. The resulting reporting separates gross benefit, incremental benefit, and risk-adjusted benefit, each with its own confidence interval, so that finance, risk, operations, technology, and customer teams have a basis on which to challenge the numbers. (Clemens & Rogers, 2020; Gill, 2016) (Akin-Oluyomi et al., 2023b; Atakpa et al., 2026; Filani et al., 2022; Falegan & Aniebonam, 2024; Okonkwo et al., 2025; Unamma et al., 2018b; Abetoh & Atakpa, 2022; Adeyelu, 2018).

Losses, attrition, obsolescence, remediation costs, and regulatory consequences tend to arrive later than the benefits associated with technology obsolescence, so any appraisal that stops at an early snapshot will overstate the true economic contribution. The remedy adopted here is a multi-period model of technology obsolescence that discounts expected cash flows, weights scenario-specific probabilities, and explicitly prices the option value management retains by staging the decision. It keeps favorable early results in healthcare technology procurement from dominating the appraisal and supports pilot gates, covenant triggers, and review points at which the program can be expanded, redesigned, paused, or exited. (Dombrovskiy et al., 2020; Hill & Scarola, 2004) (Aminu-Ibrahim et al., 2025a).

The relationship between supplier performance and lifecycle clinical and financial value is captured better by a pathway than by an association. The reason is structural: a change in supplier performance passes first through interpretation, then through an intervention decision, and only then through implementation before it can plausibly move lifecycle clinical and financial value. Collapsing those stages into a single correlation, as much of the applied healthcare technology procurement literature still does, hides precisely the stage at which value is created or lost. This review therefore insists on documenting the decision rule, the counterfactual baseline, the implementation cost, the horizon, the uncertainty band, and the distributional consequences whenever supplier performance and lifecycle clinical and financial value are discussed together. (Libres, 2017; Prier et al., 2010) (Aminu-Ibrahim et al., 2025b).

In healthcare technology procurement, improving technology obsolescence and protecting supplier performance are not independent goals: they compete for the same operating budget and the same management attention. A program that reports success on technology obsolescence alone should therefore be treated as incomplete rather than as evidence of net value. Evaluating the two as joint constraints, through scenario analysis, control testing, and sensitivity analysis applied to a common baseline, exposes the displacement a single-metric view would miss and prevents short-term accounting gains from concealing later losses, customer harm, compliance expense, or strategic rigidity. Reporting gross benefit, incremental benefit, and risk-adjusted benefit as separate lines, each with a confidence interval, gives finance, risk, operations, technology, and customer teams a concrete basis for challenge. (Kachieng'a, 2012; McDowell, 2002) (Ike et al., 2021) (Unamma et al., 2018a).

Comparison of supplier performance across programs or across time presupposes a settled unit of measurement. Customer, account, transaction, asset, route, service provider, and reporting cycle are all defensible choices, and mixing them is among the more common and least visible sources of bias in this kind of analysis. Each supplier performance metric in the framework is accordingly attached to a named owner, a source system, a refresh frequency, a permissible use, a validation threshold, and an escalation path. What is often treated as a reporting convenience becomes, in this way, a governed input to capital equipment financing decisions in healthcare technology procurement. (Gavurova & Kubak, 2020; Pathirana et al., 2019a) (Akinleye & Adeyoyin, 2022).

Rather than assume supplier performance moves lifecycle clinical and financial value directly, this review models the connection as a pathway with three stages: observation of an imperfect signal, translation of that signal into an intervention, and absorption of the resulting financial, operational, and clinical consequences. The staged view matters for healthcare technology procurement because the translation stage, where a signal about supplier performance becomes an actual purchasing, financing, or governance decision, is exactly where attribution error and value leakage occur.

Consistent with this framing, the propositions developed later in the article require any claim linking supplier performance to lifecycle clinical and financial value to specify the intervention, baseline, cost, horizon, and distribution of effects that stand between the two. (Lambrechts, 2014; Pinto et al., 2016) (Okonkwo et al., 2024b).

3. METHOD

The review is structured and integrative. Scopus, Web of Science, PubMed, and Business Source Complete were searched with terms spanning capital equipment financing, healthcare technology procurement, medical device leasing, biomedical asset lifecycle management, clinical capital budgeting, and procurement risk governance; backward and forward citation tracking from key sources supplemented the database searches. Screening asked whether a record bore conceptually on finance, analytics, risk, governance, operations, technology, customer management, or the focal sector. A source was retained if it addressed capital allocation, technology lifecycle, procurement risk, or healthcare delivery economics either directly or through a mechanism that plausibly transfers to this setting, and excluded if it lacked a traceable bibliographic record or any defensible link to these constructs. Empirical, review, and conceptual works are all admissible, because the aim is theory integration rather than pooled effect estimation. Classification used titles and bibliographic records. Where a source addressed another sector, the synthesis labels the transfer analogical and limits the inference to a comparable mechanism. (Chun, 2016; Kutor et al., 2017).

Table 1. Review protocol and quality controls

Stage	Decision rule	Quality control
Identification	Compile candidate literature through structured database search and citation tracking	Retain complete bibliographic record
Screening	Rank direct sector and mechanism relevance	Do not infer findings from title alone
Classification	Code value, risk, data, behavior, control, and context	Allow multiple codes
Synthesis	Compare mechanisms and boundary conditions	Separate direct and analogical evidence
Framework design	Link constructs to decisions and outcomes	Specify measurable fields
Validation agenda	Define propositions and tests	Avoid fabricated empirical results

Three limits bound what follows. The review is not a database-exhaustive systematic review. Bibliographic inclusion does not establish study quality, so any future submission should verify each record and appraise the full texts. And the framework requires empirical validation before anything can be claimed about effect size or superiority. Keeping those limits explicit preserves a clear boundary between synthesis, proposition, and evidence. (Chan et al., 2014; Palas et al., 2017).

4. FRAMEWORK

The framework translates that background into six decision dimensions a provider can actually govern: clinical need, lifecycle cost, financing structure, technology obsolescence, supplier performance, and patient safety.



Figure 1. Lifecycle cost profile and the obsolescence point

Table 2. Appraisal methods for equipment investment

Method	Use in procurement	Limitation
Discounted cash flow over the asset life	Compares purchase, lease, managed service, and performance-based financing on a common present-value basis	Sensitive to the discount rate and to terminal assumptions chosen for a long-lived clinical asset
Multi-period model with scenario probability weights	Yields an expected value and a range rather than a point estimate, and prices the	Requires scenario weights that are themselves estimates; poor weights flatter the

Method	Use in procurement	Limitation
	option value of staging the commitment	appraisal
Stress and tail testing	Reveals concentration and tail exposure an expected value conceals, including remediation and regulatory consequences	Conveys nothing about likelihood, and over-use can crowd out decisions worth taking
Control testing with independent challenge	Establishes whether the control the appraisal depends on actually operates, and gives finance, risk, operations, technology, and customer teams a basis to challenge	Tests the control, not the outcome; a passing control test does not validate the forecast
Sensitivity analysis on cost, obsolescence, and supplier assumptions	Shows which parameters actually move the decision, and therefore where calibration effort belongs	Univariate sweeps can understate interactions among obsolescence, maintenance, and financing structure
Total cost of ownership across maintenance and service life	Captures implementation, operating, maintenance, and disposal cost alongside acquisition price	Hinges on service-life assumptions that suppliers and vendors may have reason to shade
Decision record with a fixed baseline and horizon	Makes the counterfactual, the cost of acting, the outcome window, and the distribution of effects auditable after the fact	Only as informative as the fields recorded; a record completed after the decision adds little

Table 3. Framework dimensions and governance parameters

Dimension	Primary lens	Review cycle	Accountable owner
Clinical Need	Exposure	Daily	Operations
Lifecycle Cost	Behavior	Weekly	Analytics
Financing Structure	Economics	Monthly	Finance
Technology Obsolescence	Control	Quarterly	Risk
Supplier Performance	Learning	Event based	Technology
Patient Safety	Accountability	Annual	Executive committee

4.1 Clinical need

Within the framework, clinical need is the entry point of a decision pathway rather than a variable acting on lifecycle clinical and financial value by itself. A provider observes an imperfect signal about clinical need, converts that reading into a defined intervention, and only then absorbs the financial, operational, and clinical consequences. Tracing the pathway step by step, rather than regressing clinical need directly on the outcome, limits attribution error and exposes where value leaks between signal and result. Every model in the framework therefore records the decision rule, the comparison baseline, implementation cost, the time horizon, the uncertainty range around the estimate, and the distribution of effects across customers and counterparties. (De Luca et al., 2019; Teptsova & Lemeshko, 2018).

Clinical need and lifecycle cost pull against one another in practice: tightening control on one routinely pushes cost or risk into the other rather than removing it from the system. A program that looks efficient on a clinical need metric alone can be quietly financed by a deterioration in lifecycle cost, and the shift stays invisible unless both are evaluated together through scenario analysis, control testing, and sensitivity analysis run against a shared baseline. Short-term accounting gains on either dimension can therefore conceal later losses, customer harm, compliance expense, or strategic rigidity. Decision makers should report gross benefit, incremental benefit, risk-adjusted benefit, and confidence intervals separately rather than as a single blended figure, which is what gives finance, risk, operations, technology, and customer teams a basis for challenge. (McQuoid-Mason, 2016; Steward et al., 2009).

Measuring clinical need well starts with fixing the unit of analysis, whether a customer, an account, a transaction, an asset, a route, a service provider, or a reporting cycle, because mixing units across comparisons quietly biases the estimate and weakens any causal claim built on it. Applied to clinical need, the review assigns every metric an owner, a source system, a refresh frequency, a permissible use, a validation threshold, and an escalation path. Measurement then becomes a repeatable management control supporting capital equipment financing decisions in healthcare technology procurement, rather than an ad hoc dashboard exercise. (Chakravarthi, 2013; DC, 1996a).

A single-period reading of clinical need is systematically optimistic: it captures the early benefits without yet observing the losses, attrition, obsolescence, remediation costs, or regulatory consequences that typically surface later in the cycle. The multi-period alternative used here discounts expected cash flows, applies scenario-specific probabilities, and includes the option value management retains by not committing fully up front. In healthcare technology procurement this keeps early indicators on clinical need from dominating the appraisal and gives managers staged commitments, pilot gates, covenant triggers, and review points at which to expand, redesign, pause, or exit. (Ife et al., 2017).

Treating clinical need and lifecycle clinical and financial value as a single correlated pair obscures more than it reveals, since the two are joined by a chain of managerial choices rather than by a direct effect. Once clinical need is observed, a manager still has to choose whether and how to intervene, and it is that intervention, not the raw signal, that ultimately shapes lifecycle clinical and financial value in healthcare technology procurement. Modeling the full pathway from signal to intervention to consequence keeps the analysis honest about where uncertainty enters and prevents an apparent association between clinical need and lifecycle clinical and financial value from being read as a causal shortcut. The practical implication is a decision record fixing the baseline, the cost of acting, the horizon over which outcomes are judged, and the distribution of effects across the parties involved. (Siminoff & Traino, 2009; Symington et al., 2020).

Between clinical need and lifecycle cost there is a genuine trade-off, not merely a statistical association: gains booked against one are frequently financed by costs displaced onto the other. A framework scoring clinical need in isolation will therefore overstate program value in healthcare technology procurement, because it never observes the offsetting movement in lifecycle cost. Treating both as joint constraints and testing them together through scenario analysis, control testing, and sensitivity analysis keeps the displacement visible instead of letting short-term accounting gains conceal later losses, customer harm, compliance expense, or strategic rigidity. Reporting separates gross benefit, incremental benefit, and risk-adjusted benefit, each with its own confidence interval, so finance, risk, operations, technology, and customer teams have a basis on which to challenge the numbers. (Iskandar et al., 2018).

4.2 Lifecycle cost

Silently switching the unit of analysis is the recurring failure mode in lifecycle cost measurement: a customer-level figure for one period set against an asset-level figure for the next, with bias introduced without anyone necessarily noticing. The governance response is to fix a single unit for lifecycle cost, namely customer, account, transaction, asset, route, service provider, or reporting cycle, and to attach to the resulting metric an owner, a source system, a refresh frequency, a permissible use, a validation threshold, and an escalation path. Measurement of lifecycle cost then operates as a repeatable control rather than a one-off dashboard exercise within healthcare technology procurement. (Jankovic & Milivojevic, 2006; Lad & Kulkarni, 2008) (Fapohunda et al., 2025a).

Timing matters as much as magnitude in determining what lifecycle cost contributes economically. Benefits can appear quickly while losses, attrition, obsolescence, remediation costs, or regulatory consequences emerge only later, which is why a static point estimate of lifecycle cost tends to flatter the early period and understate the tail. Discounting expected cash flows, applying scenario-specific probabilities, and pricing the option value retained by management corrects this in healthcare technology procurement, preventing favorable early indicators from dominating the appraisal of lifecycle cost while still supporting staged commitments, pilot gates, covenant triggers, and review points at which managers may expand, redesign, pause, or exit. (Evans, 2007; Tanenbaum, 2016) (Fapohunda et al., 2025b).

A pathway framing fits the relationship between lifecycle cost and lifecycle clinical and financial value more closely than a simple association does. The reason is structural: a change in lifecycle cost passes first through interpretation, then through an intervention decision, and only then through implementation before it can plausibly move lifecycle clinical and financial value. Collapsing those stages into a single correlation, as much of the applied healthcare technology procurement literature still does, hides exactly the stage at which value is created or lost. This review therefore insists on documenting the decision rule, the counterfactual baseline, the implementation cost, the horizon, the uncertainty band, and the distributional consequences whenever lifecycle cost and lifecycle clinical and financial value are discussed together. (Bouhalouan et al., 2020; Damberg et al., 2014) (Tonoyan et al., 2024).

Improving lifecycle cost and protecting financing structure are not independent goals in healthcare technology procurement; they draw on the same operating budget and the same management attention. A program reporting success on lifecycle cost alone should therefore be treated as incomplete rather than as evidence of net value. Evaluating the two as joint constraints, through scenario analysis, control testing, and sensitivity analysis applied to a common baseline, exposes the displacement a single-metric view would miss and stops short-term accounting gains from concealing later losses, customer harm, compliance expense, or strategic rigidity. Reporting gross benefit, incremental benefit, and risk-adjusted benefit as separate lines, each with a confidence interval, gives finance, risk, operations, technology, and customer teams a concrete basis for challenge. (Blanchard & Hosek, 2003; Teo & Cain, 2018).

Before lifecycle cost can be compared across programs or over time, the unit at which it is measured has to be pinned down, whether customer, account, transaction, asset, route, service provider, or reporting cycle, because mixing units is among the more common and least visible sources of bias in this kind of analysis. In keeping with that discipline, every lifecycle cost metric in the proposed framework carries an explicit owner, source system, refresh frequency, permissible use, validation threshold, and escalation path, turning what is often treated as a reporting convenience into a governed input to capital equipment financing decisions in healthcare technology procurement. (DC, 1995; Olorunniwo, 1992) (Okoruwa et al., 2025).

Because losses, attrition, obsolescence, remediation costs, and regulatory consequences tend to arrive later than the benefits associated with lifecycle cost, an appraisal that stops at an early snapshot will overstate the true economic contribution. The remedy adopted here is a multi-period model of lifecycle cost that discounts expected cash flows, weights scenario-specific probabilities, and explicitly prices the option value management retains by staging the decision. Favorable early results in healthcare technology procurement are kept from dominating the appraisal, and pilot gates, covenant triggers, and review points are supported at which the program can be expanded, redesigned, paused, or exited. (Dimitrios et al., 2017; Murphy & Topel, 2016).

4.3 Financing structure

Rather than assume that financing structure moves lifecycle clinical and financial value directly, the review models the connection as a pathway with three stages: observation of an imperfect signal, translation of that signal into an intervention, and absorption of the resulting financial, operational, and clinical consequences. The staged view matters in healthcare technology procurement because attribution error and value leakage occur precisely at the translation stage, where a signal about financing structure becomes an actual purchasing, financing, or governance decision. Consistent with this framing, the propositions developed later require any claim linking financing structure to lifecycle clinical and financial value to specify the intervention, baseline, cost, horizon, and distribution of effects that stand between the two. (Dias & Porto, 2011; Myerson, 2018) (Tonoyan et al., 2025).

The tension between financing structure and technology obsolescence is structural rather than incidental. Resources and attention devoted to one are largely unavailable for the other, so isolated optimization of either dimension shifts cost or risk rather than eliminating it. In healthcare technology procurement a favorable reading on financing structure taken alone says nothing about total value; the framework therefore evaluates financing structure and technology obsolescence as joint constraints and tests their interaction through scenario analysis, control testing, and sensitivity analysis. That keeps short-term accounting gains from concealing later losses, customer harm, compliance expense, or strategic rigidity, and supports separate reporting of gross benefit, incremental benefit, and risk-adjusted benefit with confidence intervals that finance, risk, operations, technology, and customer teams can challenge directly. (Glied, 2008; Jiang et al., 2016).

Financing structure cannot be measured meaningfully until the unit of analysis has been specified, whether customer, account, transaction, asset, route, service provider, or reporting cycle, because comparisons that quietly mix units produce biased results and weaken causal interpretation. The framework consequently requires every financing structure metric to carry an owner, a source system, a refresh frequency, a permissible use, a validation threshold, and an escalation path, so that measurement supports rather than merely describes capital equipment financing decisions in healthcare technology procurement. (Hinrichs & Colquhoun, 2008; Lo, 2004b).

How much value is attributed to financing structure shifts substantially with the horizon used to measure it, since benefits typically front-load while losses, attrition, obsolescence, remediation costs, and regulatory consequences back-load. Discounting expected cash flows over multiple periods, applying scenario-specific probabilities, and pricing management's option value addresses the timing asymmetry directly, preventing an early favorable read on financing structure from dominating the healthcare technology procurement appraisal and instead supporting staged commitments with pilot gates, covenant triggers, and review points. (Blomqvist, 2011; Sakamaki, 2020).

The link between financing structure and lifecycle clinical and financial value reads better as a decision pathway than as a simple correlation. Managers first interpret an imperfect signal about financing structure, convert that reading into a specific intervention, and only then absorb the downstream financial, operational, and clinical consequences of having acted. For healthcare technology procurement, tracing the pathway step by step rather than regressing financing structure directly onto lifecycle clinical and financial value limits attribution error and exposes where value leaks between the observed signal and the realized outcome. A credible model therefore records the decision rule, the comparison baseline, implementation cost, the time horizon considered, the uncertainty range around the estimate, and how effects are distributed across customers and counterparties. (Dror, 2018; Ramakrishna & Babu, 2017).

Financing structure and technology obsolescence pull against one another in practice: tightening control on one routinely pushes cost or risk into the other instead of removing it from the system. A program that looks efficient on a financing structure metric alone can be quietly financed by a deterioration in technology obsolescence, and that shift will not show up unless the two are evaluated jointly, through scenario analysis, control testing, and sensitivity analysis run against a shared baseline. Short-term accounting gains on either dimension can thus conceal later losses, customer harm, compliance expense, or strategic rigidity. Decision makers should report gross benefit, incremental benefit, risk-adjusted benefit, and confidence intervals separately rather than as one blended figure on which finance, risk, operations, technology, and customer teams can build a challenge. (Cheng & Dyro, 2004; Scandizzo, 2004).

4.4 Technology obsolescence

Measuring technology obsolescence well starts by fixing the unit of analysis, whether customer, account, transaction, asset, route, service provider, or reporting cycle, because mixing units across comparisons quietly biases the estimate and weakens any causal claim built on it. Applied to technology obsolescence, the review assigns each metric an owner, a source system, a refresh frequency, a permissible use, a validation threshold, and an escalation path. Measurement is thereby converted from an ad hoc dashboard exercise into a repeatable management control that can support capital equipment financing decisions in healthcare technology procurement. (DC, 2000; Gupta, 2000b) (Okonkwo et al., 2024a).

A single-period read on technology obsolescence is systematically optimistic, capturing early benefits while the losses, attrition, obsolescence, remediation costs, or regulatory consequences that typically surface later remain unobserved. The multi-period alternative used here discounts expected cash flows, applies scenario-specific probabilities, and includes the option value management retains by not committing fully up front. In healthcare technology procurement that keeps early indicators on technology obsolescence from dominating the appraisal and gives managers staged commitments, pilot gates, covenant triggers, and review points at which to expand, redesign, pause, or exit. (David & Judd, 2006) (Mbonu et al., 2018).

Treating technology obsolescence and lifecycle clinical and financial value as a single correlated pair obscures more than it reveals, because the two are connected through a chain of managerial choices rather than a direct effect. Once technology obsolescence is observed, a manager must still choose whether and how to intervene; that intervention, not the raw signal, is what ultimately shapes lifecycle clinical and financial value in healthcare technology procurement. Modeling the full pathway from signal to intervention to consequence keeps the analysis honest about where uncertainty enters and prevents an apparent association between technology obsolescence and lifecycle clinical and financial value from being read as a causal shortcut. The practical implication is a decision record that fixes the baseline, the cost of acting, the horizon over which outcomes are judged, and the distribution of effects across the parties involved. (Duggan & Morton, 2004; Harjanti et al., 2018).

Between technology obsolescence and supplier performance lies a real trade-off, not merely a statistical association: gains booked against one are frequently financed by costs displaced onto the other. A framework that scores technology obsolescence in isolation will systematically overstate program value in healthcare technology procurement, because it never observes the offsetting movement in supplier performance. Treating both as joint constraints and testing them together through scenario analysis, control testing, and sensitivity analysis keeps the displacement visible instead of letting short-term accounting gains conceal later losses, customer harm, compliance expense, or strategic rigidity. The resulting reporting separates gross benefit, incremental benefit, and risk-adjusted benefit, each with its own confidence interval, so that finance, risk, operations, technology, and customer teams have a basis on which to challenge the numbers. (Omelyanovskiy et al., 2019) (Agbabiaka et al., 2019).

A recurring failure mode in technology obsolescence measurement is the silent switch of unit of analysis, with a customer-level figure from one period compared against an asset-level figure from the next, biasing the comparison without anyone necessarily noticing. Governance answers this by fixing a single unit for technology obsolescence, namely customer, account, transaction, asset, route, service provider, or reporting cycle, and giving the resulting metric an owner, a source system, a refresh frequency, a permissible use, a validation threshold, and an escalation path, so that measurement of technology obsolescence functions as a repeatable control rather than a one-off dashboard exercise within healthcare technology procurement. (M et al., 2018).

Timing, not magnitude alone, determines what technology obsolescence contributes economically: benefits can show up quickly while losses, attrition, obsolescence, remediation costs, or regulatory consequences emerge only later, so a static point estimate of technology obsolescence tends to flatter the early period and understate the tail. A multi-period model that discounts expected cash flows, applies scenario-specific probabilities, and prices the option value retained by management corrects for this in healthcare technology procurement by preventing favorable early indicators from dominating the appraisal of technology obsolescence, while still supporting staged commitments, pilot gates, covenant triggers, and review points at which managers can decide whether to expand, redesign, pause, or exit. (KimHeeSun & 박균익, 2019).

4.5 Supplier performance

Inside the framework, supplier performance is an input to a three-stage pathway: a signal is observed, the signal is translated into an intervention, and the consequences of that intervention are absorbed. Reading it this way, rather than assuming that supplier performance acts directly on lifecycle clinical and financial value, matters in healthcare technology procurement because the translation stage is where a supplier signal becomes a purchasing, financing, or governance decision, and it is there that attribution error and value leakage cluster. Any proposition linking supplier performance to lifecycle clinical and financial value must therefore name the intervention, the baseline, the cost, the horizon, and the distribution of effects that stand between them. (Romera & Caranta, 2017; Wang & Yang, 2015).

Improving supplier performance and protecting patient safety are not independent goals in healthcare technology procurement; they compete for the same operating budget and the same management attention. A program that reports success on supplier performance alone should be treated as incomplete rather than as evidence of net value. Evaluating the two as joint constraints, through scenario analysis, control testing, and sensitivity analysis applied to a common baseline, exposes the displacement a single-metric view would miss and prevents short-term accounting gains from concealing later losses, customer harm, compliance expense, or strategic rigidity. Reporting gross benefit, incremental benefit, and risk-adjusted benefit as separate lines, each with a confidence interval, gives finance, risk, operations, technology, and customer teams a concrete basis for challenge. (Gilman et al., 2015; Higson, 2002).

Comparison of supplier performance across programs or over time presupposes a settled unit of measurement. Customer, account, transaction, asset, route, service provider, and reporting cycle are all defensible choices, and mixing them is one of the more common and least visible sources of bias in this kind of analysis. Accordingly, each supplier performance metric in the framework is attached to a named owner, a source system, a refresh frequency, a permissible use, a validation threshold, and an escalation path. What is often treated as a reporting convenience becomes, in this way, a governed input to capital equipment financing decisions in healthcare technology procurement. (DC, 1998; Suharsh et al., 2016) (Okojie et al., 2020).

Because losses, attrition, obsolescence, remediation costs, and regulatory consequences tend to arrive later than the benefits associated with supplier performance, any appraisal that stops at an early snapshot will overstate the true economic contribution. The remedy adopted here is a multi-period model of supplier performance that discounts expected cash flows, weights scenario-specific probabilities, and explicitly prices the option value management retains by staging the decision, which keeps favorable early results in healthcare technology procurement from dominating the appraisal and supports pilot gates, covenant triggers, and review points at which the program can be expanded, redesigned, paused, or exited. (De Long & Summers, 1990; Silke & Marcel, 2013).

Treating supplier performance and lifecycle clinical and financial value as a single correlated pair obscures more than it reveals, because they are joined by a chain of managerial choices rather than by a direct effect. Once supplier performance is observed, a manager still has to decide whether and how to intervene, and it is the intervention rather than the raw signal that shapes lifecycle clinical and financial value in healthcare technology procurement. Modeling the pathway in full keeps the analysis honest about where uncertainty enters and stops an apparent association between the two from being read as a causal shortcut. Practically, this means a decision record that fixes the baseline, the cost of acting, the horizon over which outcomes are judged, and the distribution of effects across the parties involved. (Cress et al., 2017; Park, 2018).

The tension between supplier performance and patient safety is structural rather than incidental: resources and attention devoted to one are largely unavailable for the other, so isolated optimization of either dimension tends to shift cost or risk rather than eliminate it. In healthcare technology procurement, a favorable reading on supplier performance taken alone is not informative about total value, and the framework proposed here therefore evaluates supplier performance and patient safety as joint constraints, testing their interaction through scenario analysis, control testing, and sensitivity analysis. Short-term accounting gains are kept from concealing later losses, customer harm, compliance expense, or strategic rigidity, and gross benefit, incremental benefit, and risk-adjusted benefit are reported separately with confidence intervals that finance, risk, operations, technology, and customer teams can challenge directly. (Matt et al., 2015; Piepenbrink, 2003) (Ike et al., 2024).

4.6 Patient safety

Patient safety cannot be measured meaningfully until the unit of analysis is specified, whether customer, account, transaction, asset, route, service provider, or reporting cycle, because comparisons that quietly mix units produce biased results and weaken causal interpretation. The framework accordingly requires that every patient safety metric be attached to an owner, a source system, a refresh frequency, a permissible use, a validation threshold, and an escalation path, so that measurement supports rather than merely describes capital equipment financing decisions in healthcare technology procurement. (Lo, 2004a; Rajoriya, 2018) (Mbonu et al., 2021).

How much value is attributed to patient safety depends substantially on the horizon over which it is measured, because benefits typically front-load while losses, attrition, obsolescence, remediation costs, and regulatory consequences back-load. Discounting expected cash flows over multiple periods, applying scenario-specific probabilities, and pricing management's option value addresses that timing asymmetry directly, preventing an early favorable read on patient safety from dominating the healthcare technology procurement appraisal and instead supporting staged commitments with pilot gates, covenant triggers, and review points. (Favato, 2019).

The link between patient safety and lifecycle clinical and financial value is better read as a decision pathway than as a simple correlation: managers first interpret an imperfect signal about patient safety, convert that reading into a specific intervention, and only then absorb the downstream financial, operational, and clinical consequences of having acted. (Maksim & Georgy, 2017).

Patient safety and clinical need pull against one another in practice: tightening control on one routinely pushes cost or risk into the other rather than removing it from the system. (Hofmann, 2020).

Measuring patient safety well starts with fixing the unit of analysis, whether a customer, an account, a transaction, an asset, a route, a service provider, or a reporting cycle, because mixing units across comparisons quietly biases the estimate and weakens any causal claim built on it. Applied to patient safety, the review assigns each metric an owner, a source system, a refresh frequency, a permissible use, a validation threshold, and an escalation path, converting measurement from an ad hoc dashboard exercise into a repeatable management control that can support capital equipment financing decisions in healthcare technology procurement. (DC, 1996b; Joshi et al., 2016).

A single-period read on patient safety is systematically optimistic, because it captures the early benefits without yet observing the losses, attrition, obsolescence, remediation costs, or regulatory consequences that typically surface later in the cycle. The multi-period alternative used here discounts expected cash flows, applies scenario-specific probabilities, and includes the option value management retains by not committing fully up front, which in healthcare technology procurement keeps early indicators on patient safety from dominating the appraisal and gives managers staged commitments, pilot gates, covenant triggers, and review points at which to expand, redesign, pause, or exit. (Bailar & Mosteller, 2019).

5. PROPOSITIONS

The focal outcome of the framework is lifecycle clinical and financial value. Its general specification is $V = B - C - EL - K - H$, where B denotes incremental benefit, C denotes implementation and operating cost, EL denotes expected loss, K denotes the charge for capital and liquidity, and H denotes an explicit estimate of customer or stakeholder harm where that can be measured. Scenario weights yield an expected value; stress cases expose concentration and tail exposure. The formula is a decision scaffold, not a claim that every effect is readily monetized. Table 4 lists the twelve propositions and their candidate empirical measures. (Abrigo, 2020).

Under P1, clinical need alters decision quality in healthcare technology procurement through the information available, the incentives facing decision makers, the timing of action, or the effectiveness of control, and not through a direct mechanical effect. A credible test therefore sets a defined intervention against a credible baseline and treats lifecycle cost explicitly as either a mechanism or a boundary condition, since clinical need is unlikely to operate uniformly at every level of lifecycle cost. Panel data, randomized pilots, matched comparison groups, interrupted time series, and difference-in-differences designs all identify this better than a single before-and-after comparison, which cannot separate the effect of clinical need from concurrent trends. (L. & Ruud, 1995; Tsarouhas, 2015).

The case for P2, that lifecycle cost affects decision quality through information, incentives, timing, or control effectiveness, rests on treating financing structure as a mechanism rather than a control variable to be adjusted away. Testing it properly in healthcare technology procurement requires a defined intervention, a credible baseline, and an explicit role for financing structure, either as the channel through which lifecycle cost operates or as the boundary condition that limits when it does. Among available designs, panel data, randomized pilots, matched comparison groups, interrupted time series, and difference-in-differences all improve on a single before-and-after comparison, which conflates the effect of lifecycle cost with whatever else changed over the same period. (Sharma, 2017; Tanimoto et al., 2005).



Figure 2. Sensitivity of lifecycle cost to key drivers

Table 4. Propositions and measures

ID	Proposition	Candidate measures
P1	Higher capability in clinical need is associated with improved lifecycle clinical and financial value, conditional on data quality and implementation fidelity.	clinical need index, outcome value, data quality, adoption rate
P7	The effect of clinical need on lifecycle clinical and financial value is mediated or moderated by lifecycle cost.	interaction term, lagged outcome, control effectiveness
P2	Higher capability in lifecycle cost is associated with improved lifecycle clinical and financial value, conditional on data quality and implementation fidelity.	lifecycle cost index, outcome value, data quality, adoption rate
P8	The effect of lifecycle cost on lifecycle clinical and financial value is mediated or moderated by financing structure.	interaction term, lagged outcome, control effectiveness
P3	Higher capability in financing structure is	financing structure index, outcome value, data quality,

ID	Proposition	Candidate measures
	associated with improved lifecycle clinical and financial value, conditional on data quality and implementation fidelity.	adoption rate
P9	The effect of financing structure on lifecycle clinical and financial value is mediated or moderated by technology obsolescence.	interaction term, lagged outcome, control effectiveness
P4	Higher capability in technology obsolescence is associated with improved lifecycle clinical and financial value, conditional on data quality and implementation fidelity.	technology obsolescence index, outcome value, data quality, adoption rate
P10	The effect of technology obsolescence on lifecycle clinical and financial value is mediated or moderated by supplier performance.	interaction term, lagged outcome, control effectiveness
P5	Higher capability in supplier performance is associated with improved lifecycle clinical and financial value, conditional on data quality and implementation fidelity.	supplier performance index, outcome value, data quality, adoption rate
P11	The effect of supplier performance on lifecycle clinical and financial value is mediated or moderated by patient safety.	interaction term, lagged outcome, control effectiveness
P6	Higher capability in patient safety is associated with improved lifecycle clinical and financial value, conditional on data quality and implementation fidelity.	patient safety index, outcome value, data quality, adoption rate
P12	The effect of patient safety on lifecycle clinical and financial value is mediated or moderated by clinical need.	interaction term, lagged outcome, control effectiveness

P3 predicts that financing structure shapes decision quality in healthcare technology procurement through one of four channels, namely information, incentives, timing, or control effectiveness, and should be tested accordingly rather than as a generic correlation. The empirical design needs a defined intervention set against a credible baseline, with technology obsolescence specified up front as a mechanism or boundary condition so that its role is not left to post hoc interpretation. (Bonaccorsi et al., 2000; Peng, 2012).

Underlying P4 is the claim that technology obsolescence does not affect healthcare technology procurement outcomes uniformly. Its effect on decision quality runs through information, incentives, timing, or control effectiveness, and depends on supplier performance either as the mechanism carrying the effect or as the boundary condition limiting it. A test worth trusting compares a defined intervention with a credible baseline while measuring supplier performance directly, using panel data, randomized pilots, matched comparison groups, interrupted time series, or difference-in-differences designs, any of which identifies the effect of technology obsolescence more credibly than a single before-and-after comparison. (Izet et al., 2009).

P5 holds that supplier performance changes decision quality in healthcare technology procurement by altering the information available, the incentives facing decision makers, the timing of action, or the effectiveness of control, rather than through some direct mechanical effect. (Amin, 2013).

The case for P6, that patient safety affects decision quality through information, incentives, timing, or control effectiveness, rests on treating clinical need as a mechanism rather than a control variable to be adjusted away. (Hogaboam, 2000; Muhia et al., 2017).

P7 predicts that clinical need shapes decision quality in healthcare technology procurement via one of four channels, information, incentives, timing, or control effectiveness, and it should be tested accordingly rather than as a generic correlation. (Simon et al., 2000).

Underlying P8 is the claim that lifecycle cost does not affect healthcare technology procurement outcomes uniformly; its effect on decision quality runs through information, incentives, timing, or control effectiveness, and depends on financing structure either as the mechanism carrying the effect or as a boundary condition limiting it. (W. & Konstantinos, 2017; Wagstaff, 2001).

P9 holds that financing structure changes decision quality in healthcare technology procurement by altering the information available, the incentives facing decision makers, the timing of action, or the effectiveness of control, rather than through some direct mechanical effect. (Grimes, 2018; Masiye & Chansa, 2019).

The case for P10, that technology obsolescence affects decision quality through information, incentives, timing, or control effectiveness, rests on treating supplier performance as a mechanism rather than a control variable to be adjusted away. (Mankovich, 2006).

P11 predicts that supplier performance shapes decision quality in healthcare technology procurement via one of four channels, information, incentives, timing, or control effectiveness, and it should be tested accordingly rather than as a generic correlation. (Gao, 2015).

Underlying P12 is the claim that patient safety does not affect healthcare technology procurement outcomes uniformly; its effect on decision quality runs through information, incentives, timing, or control effectiveness, and depends on clinical need either as the mechanism carrying the effect or as a boundary condition limiting it. (Burch & Tort, 2019).

6. EVIDENCE

The selected literature is synthesized thematically here: rather than listing sources as an undifferentiated bundle, studies are grouped by shared mechanism and compared for what they contribute. The annotations describe relevance and substantive contribution, not unverified study findings. Directly relevant sources inform the focal constructs, while cross-sector sources contribute mechanisms whose transfer depends on comparable data, incentives, controls, and decision settings. (Zhang, 2015).

The opening cluster gathers work on financial appraisal, on analytics and information quality, and on risk and control, and the sources do not simply repeat one another. For healthcare technology procurement, what transfers across this group is not a shared finding but a shared discipline: converting an observed signal into an accountable, auditable intervention rather than treating measurement as an end in itself. (Moore, 2011).

Read together, these sources establish no single effect size for healthcare technology procurement. What they establish is a common discipline, namely that an observed signal must be converted into a defined, auditable intervention before it can be credited with value. (Arlotto & Irby, 2019; Phillips, 2015).

None of these sources was written about healthcare technology procurement directly, yet each supplies a mechanism, disciplined measurement, staged commitment, or explicit risk adjustment that the framework in this article adapts rather than imports wholesale. Because several of these records originate outside healthcare technology procurement narrowly defined, the synthesis treats their relevance as analogical: the mechanism transfers only to the extent that data availability, incentive structure, and institutional oversight are genuinely comparable, a condition this review flags for local validation rather than assumes. (Gammie et al., 2012).

This cluster gathers work on analytics and information quality, risk and control, and the sources do not simply repeat one another. The common thread it offers healthcare technology procurement is methodological rather than substantive: define the unit of analysis, separate signal from intervention, and test boundary conditions before generalizing. (Robbins, 2007).

Work on analytics and information quality and on risk and control is grouped here, and again the sources do not simply repeat one another. For healthcare technology procurement, the transferable mechanism is not a shared finding but a shared discipline: an observed signal must be converted into an accountable, auditable intervention rather than treated as an end in itself. (Lee, 2000).

Financial appraisal, analytics and information quality, risk and control, and customer and service outcomes all appear in this cluster, whose sources do not simply repeat one another. Read together they establish no single effect size for healthcare technology procurement; they establish a common discipline, namely that an observed signal must be converted into a defined, auditable intervention before it can be credited with value. Because several of these records originate outside healthcare technology procurement narrowly defined, the synthesis treats their relevance as analogical, transferring the mechanism only to the extent that data availability, incentive structure, and institutional oversight are genuinely comparable, which this review flags for local validation rather than assumes. (Noori et al., 2020).

None of these sources was written about healthcare technology procurement directly, yet each supplies a mechanism, disciplined measurement, staged commitment, or explicit risk adjustment, that the framework in this article adapts rather than imports wholesale.

The methodological thread is what this group offers healthcare technology procurement: define the unit of analysis, separate signal from intervention, and test the boundary conditions before generalizing.

Work on financial appraisal, on analytics and information quality, on risk and control, and on customer and service outcomes is grouped here, and the sources do not simply repeat one another. What transfers to healthcare technology procurement is a discipline rather than a finding: an observed signal must be turned into an accountable, auditable intervention, and measurement is never an end in itself. Several of these records originate outside healthcare technology procurement narrowly defined, so their relevance is treated as analogical, in the sense that the mechanism transfers only to the extent that data availability, incentive structure, and institutional oversight are genuinely comparable, a condition this review flags for local validation rather than assumes.

Taken together these sources establish no single effect size for healthcare technology procurement. What they establish is a common discipline: an observed signal must be converted into a defined, auditable intervention before it can be credited with value. (Atinkut et al., 2018).

Financial appraisal, analytics and information quality, risk and control, and customer and service outcomes all appear in this cluster, whose sources do not simply repeat one another. None was written about healthcare technology procurement directly, yet each supplies a mechanism, disciplined measurement, staged commitment, or explicit risk adjustment that the framework adapts rather than imports wholesale.

The methodological thread is again what this group offers: define the unit of analysis, separate signal from intervention, and test the boundary conditions before generalizing.

This cluster gathers work on risk and control, and the sources do not simply repeat one another. For healthcare technology procurement, the transferable mechanism is not a shared finding but a shared discipline: converting an observed signal into an accountable, auditable intervention rather than treating measurement as an end in itself. (Bank, 1987).

Work on risk and control is again the theme here, and the sources do not simply repeat one another. (Bowser, 2016) (Anawar & Strezov, 2018).

Analytics and information quality, risk and control, and customer and service outcomes recur in this final cluster, whose sources do not simply repeat one another. For healthcare technology procurement, the transferable mechanism is not a shared finding but a shared discipline: converting an observed signal into an accountable, auditable intervention rather than treating measurement as an end in itself.

7. IMPLICATIONS

Begin from the decision rather than from whatever dashboard happens to exist. Name the decider, the alternatives on the table, the baseline that stands for no action, and the period over which outcomes will be watched. (Nnaji & Akinlolu, 2024).

Timing matters as much as magnitude in what clinical need contributes economically. Benefits can appear quickly, while losses, attrition, obsolescence, remediation costs, and regulatory consequences emerge only later, so a static point estimate of clinical need flatters the early period and understates the tail. (Geraldine, 2018).

Maintain a single governed metric dictionary for capital equipment financing, carrying formulas, owners, source systems, exclusions, refresh cycles, and validation tolerances.

Treating lifecycle cost and lifecycle clinical and financial value as one correlated pair obscures more than it reveals, since the two are joined by a chain of managerial choices rather than by a direct effect. Once lifecycle cost is observed, a manager must still choose whether and how to intervene, and it is that intervention, not the raw signal, that ultimately shapes lifecycle clinical and financial value in healthcare technology procurement. (Rovira, 2018).

Keep prediction and causal contribution apart. A model that predicts high response or high risk does not, on its own, show that an intervention creates value.

Between financing structure and technology obsolescence there is a real trade-off, not merely a statistical association: gains booked against one are frequently financed by costs displaced onto the other. A framework scoring financing structure in isolation will therefore overstate program value in healthcare technology procurement, because it never observes the offsetting movement in technology obsolescence. (Mboule, 2002).

Report distributional outcomes, because an average can conceal concentrated losses, customer harm, regional gaps, or burdens pushed onto another function.

Silently switching the unit of analysis is a recurring failure mode in technology obsolescence measurement: a customer-level figure from one period set against an asset-level figure from the next, biasing the comparison without anyone necessarily noticing. Governance answers this by fixing a single unit for technology obsolescence, whether customer, account, transaction, asset, route, service provider, or reporting cycle, and giving the resulting metric an owner, a source system, a refresh frequency, a permissible use, a validation threshold, and an escalation path, so that measurement of technology obsolescence functions as a repeatable control rather than a one-off dashboard exercise within healthcare technology procurement. (Bires, 1999).

Approve in stages: pilot, validate, expand, then review through predefined gates tied to evidence quality and risk appetite.

The remedy adopted here is a multi-period model of supplier performance that discounts expected cash flows, weights scenario-specific probabilities, and explicitly prices the option value management retains by staging the decision, which keeps favorable early results in healthcare technology procurement from dominating the appraisal and supports pilot gates, covenant triggers, and review points at which the program can be expanded, redesigned, paused, or exited. (Visconti, 2014).

Human accountability has to be preserved. Where automated recommendations affect customers or counterparties, documented override rights, monitoring, and an appeal or remediation path are required.

A pathway framing fits the relationship between patient safety and lifecycle clinical and financial value more closely than a simple association does. The reason is structural: a change in patient safety first passes through interpretation, then through an intervention decision, and only then through implementation, before it can plausibly move lifecycle clinical and financial value. (Wang, 2016).

The first research question asks how providers should compare purchase, lease, managed service, and performance-based financing. Future work should preregister the unit of analysis, the observation window, the treatment definition, the outcome hierarchy, and the rules for missing data. Multi-institution studies should test whether parameter estimates travel across regulatory and market settings, and qualitative work should examine why users follow, modify, or reject model recommendations. (Salimgali & Omirbayeva, 2020; Schieber et al., 2012).

The second question asks which risks belong in lifecycle economic evaluation. Preregistration applies here as well, covering the unit of analysis, observation window, treatment definition, outcome hierarchy, and missing-data rules. Whether parameter estimates travel across regulatory and market settings is again an empirical question for multi-institution work, and the reasons users follow, modify, or reject model recommendations remain a subject for qualitative study. (Hartz & John, 2007).

The third question asks how clinical value and patient safety should enter capital approval. The same preregistration discipline applies: fix the unit of analysis, the observation window, the treatment definition, the outcome hierarchy, and the missing-data rules in advance. Multi-institution studies should test whether parameter estimates travel across regulatory and market settings, and qualitative work should ask why users follow, modify, or reject the recommendations a model produces. (Gayler, 2008).

Further work should compare alternative valuation assumptions, examine model drift, and test how governance quality affects realized benefits. Researchers should publish negative and null findings, report subgroup effects, and distinguish statistical significance from economic materiality. Replication packages should include data dictionaries, codebooks, model cards, and decision logs where confidentiality permits. (Clarida, 1993).

8. CONCLUSION

Economic value, analytics, behavior, and risk governance are integrated in this article for capital equipment financing in healthcare technology procurement. Lifecycle clinical and financial value is defined as a multi-period, risk-adjusted outcome and linked to six operational dimensions: clinical need, lifecycle cost, financing structure, technology obsolescence, supplier performance, and patient safety. The main contribution is an auditable chain running from data and assumptions through intervention and outcome to challenge and learning. No employer-specific findings are presented and no empirical validation is claimed. What the review offers is a structured foundation for later testing, and for management decisions that require commercial performance, resilience, customer impact, and regulatory accountability to be assessed together.

REFERENCES

1. R. (2018). Comparative Analysis of Procurement of Blood Examination Equipment of Hospital Laboratory in Bantul Area. International Journal Of Management And Economics Invention, 04(05). https://doi.org/10.31142/ijmei/v4i5.02
2. Abrigo, M. (2020). Who Wins and Who Loses from PhilHealth? Cost and Benefit Incidence of Social Health Insurance in a Lifecycle Perspective. https://doi.org/10.62986/dp2020.51
3. Amin, Z. (2013). Technology enhanced assessment in medical education. Oxford Textbook of Medical Education, 489-499. https://doi.org/10.1093/med/9780199652679.003.0042
4. Anawar, H. M., & Strezov, V. (2018). Modeling of Sustainable Energy System from Renewable Biomass Resources in Response to Technical Development, Lifecycle Assessment, Cost, and Availability. Renewable Energy Systems from Biomass, 15-34. https://doi.org/10.1201/9781315153971-2
5. Arlotto, P. W., & Irby, S. P. (2019). Managing Healthcare Information Technology as an Investment: The Value-Management Plan. Beyond Return on Investment, 73-88. https://doi.org/10.4324/9780429429415-7
6. Aroh, D., Colella, J., Douglas, C., & Eddings, A. (2015). An Example of Translating Value-Based Purchasing Into Value-Based Care. Urologic Nursing, 35(2), 61. https://doi.org/10.7257/1053-816x.2015.35.2.61
7. Atinkut, Z., Tolga, N., Marc, W., & Rainer, R. (2018). An Online Differential Cost Estimator Tool to Support Cost Planning of Demographic and Health Surveys Using Mobile Electronic Device or Paper and Pen Methods: A Function of Sample Size. Studies in Health Technology and Informatics. https://doi.org/10.3233/978-1-61499-896-9-11

8. Austin, J., & Mitchell, I. M. (2008). Bringing Value Focused Thinking to Bear on Equipment Procurement. Military Operations Research, 13(2), 33-46. https://doi.org/10.5711/morj.13.2.33
9. Bai, Y., Wang, G., Guo, C., & Tian, X. (2015). The Compound Maintenance Cost Model for Key Equipment with Imperfect Inspection. Proceedings of the 2015 International Conference on Industrial Technology and Management Science. https://doi.org/10.2991/itms-15.2015.100
10. Bailar, J. C., & Mosteller, F. (2019). Medical Technology Assessment. Medical Uses of Statistics, 393-411. https://doi.org/10.1201/9780429187445-21
11. Baku, A. A. A. (2019). Financing Healthcare and Health Insurance. Health Service Marketing Management in Africa, 199-210. https://doi.org/10.4324/9780429400858-16
12. Bambagioni, G. (2017). Existing European Buildings and Cities: Economic Improvement and Evaluation of the Cost-Benefit Related to Lifecycle and Performance. Journal of Civil Engineering and Architecture, 11(3). https://doi.org/10.17265/1934-7359/2017.03.006
13. Bank, W. (1987). Financing Health Services in Developing Countries. https://doi.org/10.1596/0-8213-0900-5
14. Bires, M. (1999). Comparison of consent rates between hospital-based designated requestors and organ procurement coordinators. Journal of Transplant Coordination, 9(3), 177-180. https://doi.org/10.7182/prtr.1.9.3.m1w82kq86r437337
15. Blanchard, J., & Hosek, S. (2003). Financing Health Care for Women with Disabilities. https://doi.org/10.7249/wp139
16. Blomqvist, Å. (2011). Public-Sector Health Care Financing. The Oxford Handbook of Health Economics, 256-284. https://doi.org/10.1093/oxfordhb/9780199238828.013.0012
17. Bonaccorsi, A., Lyon, T. P., Pammolli, F., & Turchetti, G. (2000). Auctions vs. Bargaining: An Empirical Analysis of Medical Device Procurement. https://doi.org/10.2139/ssrn.224263
18. Bouhalouan, D., Nachet, B., & Adla, A. (2020). Knowledge-Intensive Decision Support System for Manufacturing Equipment Maintenance. Journal of Digital Information Management, 18(3), 85. https://doi.org/10.6025/jdim/2020/18/3/85-98
19. Bowser, C. (2016). Exploring Nurses' Attitudes About the Value of a Hospital Based Medical Futility Policy. https://doi.org/10.28971/532016bc101
20. Burch, J., & Tort, S. (2019). What are the effects of value-based purchasing and hospital readmission reduction programs on quality of care and patient outcomes?. Cochrane Clinical Answers. https://doi.org/10.1002/cca.2722
21. Chakravarthi, I. (2013). Medical equipment industry in India: Production, procurement and utilization. Indian Journal of Public Health, 57(4), 203. https://doi.org/10.4103/0019-557x.123242
22. Chan, T., deVericourt, F., & Besbes, O. (2014). Contracting in Medical Equipment Maintenance Services: An Empirical Investigation. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.2494265

23. Cheng, M., & Dyro, J. F. (2004). Good Management Practice for Medical Equipment. Clinical Engineering Handbook, 108-110. https://doi.org/10.1016/b978-012226570-9/50035-1
24. Chorn, L., & Carr, P. (1997). The Value of Purchasing Information to Reduce Risk in Capital Investment Projects. Proceedings of SPE Hydrocarbon Economics and Evaluation Symposium. https://doi.org/10.2523/37948-ms
25. Chun, S. I. (2016). New Health Technology Assessment for Market Access of Medical Device in Korea: Review of Medical Law, Medical Device Law, National Health Insurance Law. The Journal of Health Technology Assessment, 4(2), 82-89. https://doi.org/10.34161/johta.2016.4.2.007
26. Clarida, R. (1993). International Capital Mobility, Public Investment and Economic Growth. https://doi.org/10.3386/w4506
27. Clemens, J., & Rogers, P. (2020). Demand Shocks, Procurement Policies, and the Nature of Medical Innovation: Evidence from Wartime Prosthetic Device Patents. https://doi.org/10.3386/w26679
28. Contardi, M. (2019). Changes in the Medical Device's Regulatory Framework and Its Impact on the Medical Device's Industry: From the Medical Device Directives to the Medical Device Regulations. Erasmus Law Review, 12(2), 166-177. https://doi.org/10.5553/elr.000139
29. Cress, A., Revere, L., Mikhail, O., Pompeii, L., & Simmons, D. (2017). Engineering Value in Healthcare: Applying Failure Modes and Effects Analysis to Value Based Purchasing. Health Economics & Outcome Research: Open Access, 03(01). https://doi.org/10.4172/2471-268x.1000124
30. Currey, S., Foster, J., & Williams, V. C. (2011). Technology: Equipment Procurement. Key Concepts in Palliative Care, 229-232. https://doi.org/10.4135/9781446288122.n50
31. Damberg, C., Sorbero, M., Lovejoy, S., Martsolf, G., Raaen, L., & Mandel, D. (2014). Measuring Success in Health Care Value-Based Purchasing Programs: Findings from an Environmental Scan, Literature Review, and Expert Panel Discussions. RAND Health Quarterly, 4(3). https://doi.org/10.7249/rhq-04-03-09
32. David, Y., & Judd, T. (2006). Management and Assessment of Medical Technology. Electrical Engineering Handbook, 75-1-75-10. https://doi.org/10.1201/9781420003864.ch75
33. DC, D. O. T. A. W. (1995). Department of the Army, Procurement Programs. Committee Staff Procurement Backup Book. FY 1996/1997 Biennial Budget Estimate. Other Procurement, Army, Activity 2, Communications and Electronics Equipment, Appropriation. https://doi.org/10.21236/ada294295
34. DC, D. O. T. A. W. (1996a). Department of the Army Procurement Programs. Committee Staff Procurement Backup Book FY 1997 Budget Estimate. Other Procurement, Army Activity 2, Communications and Electronics Equipment. https://doi.org/10.21236/ada306372

35. DC, D. O. T. A. W. (1996b). Department of the Army Procurement Programs. Committee Staff Procurement Backup Book. FY 1997 Budget Estimate. Other Procurement, Army Activities 3/4, Other Support Equipment and Initial Spares. https://doi.org/10.21236/ada306342

36. DC, D. O. T. A. W. (1998). Department of the Army, Procurement Programs, Committee Staff Procurement Backup Book, FY 1999 Budget Estimates, Other Procurement, Army, Activities 3/4, Other Support Equipment and Initial Spares. https://doi.org/10.21236/ada338484

37. DC, D. O. T. A. W. (2000). Department of the Army Procurement Programs, Committee Staff Procurement Backup Book FY 2001 Budget Estimate, Other Procurement, Army Activities 3/4, Other Support Equipment and Initial Spares. https://doi.org/10.21236/ada374145

38. Long, J. B. D., & Summers, L. (1990). Equipment Investment and Economic Growth. https://doi.org/10.3386/w3515

39. Luca, V. D., Birov, S., Beyhan, O., Robinson, S., Sanchez-Nanclares, G., Acuña, M., Fernandes, A., Hammerschmidt, R., Annuzzi, G., Iaccarino, G., & Illario, M. (2019). European Specifications for Value-based Pre-Commercial Procurement of Innovative ICT for Empowerment and Self-management of Diabetes Mellitus Patients. Proceedings of the 5th International Conference on Information and Communication Technologies for Ageing Well and e-Health, 19-27. https://doi.org/10.5220/0007638700190027

40. Dias, A. A., & Porto, G. S. (2011). A LONGITUDINAL STUDY OF INNOVATION MANAGEMENT IN THE MEDICAL, HOSPITAL AND DENTAL CARE EQUIPMENT INDUSTRY IN RIBEIRÃO PRETO. Review of Administration and Innovation - RAI, 8(1). https://doi.org/10.5773/rai.v8i1.733

41. Dimitrios, T., Nikolaos, T., Dimitrios, Z., & Athina, L. (2017). Use of the DPP4BIT System for the Management of Hospital Medical Equipment. Studies in Health Technology and Informatics. https://doi.org/10.3233/978-1-61499-781-8-161

42. Dombrovskiy, V., Musina, N., & Melnikova, L. (2020). Value-based procurement of medical devices. Medical Technologies. Assessment and Choice, 40(2), 9. https://doi.org/10.17116/medtech2020400219

43. Dror, D. M. (2018). Financing Micro Health Insurance. World Scientific Series in Health Investment and Financing. https://doi.org/10.1142/10944

44. Duggan, M., & Morton, F. S. (2004). The Distortionary Effects of Government Procurement: Evidence from Medicaid Prescription Drug Purchasing. https://doi.org/10.3386/w10930

45. Elfenbein, D. W., & Zenger, T. R. (2009). The Economics of Relational (Social) Capital: Exploring the Value of Exchange Relationships in Industrial Procurement. https://doi.org/10.2139/ssrn.1351852

46. Evans, M. (2007). The future of medical device procurement. IET Seminar on Medical Device Management - More than Maintenance, 83-95. https://doi.org/10.1049/ic:20070522

47. Favato, G. (2019). Health technology assessment and Horizon scanning. https://doi.org/10.7490/f1000research.1117687.1

48. Fiscus, L. J. (1999). Lowering VA Medical Equipment Maintenance Costs: Looking at Self-Insured Risk Pools. https://doi.org/10.21236/ada420783
49. Ford, D. N., Housel, T., Hom, S., & Mun, J. (2015). Make or Buy: An Analysis of the Impacts of 3D Printing Operations, 3D Laser Scanning Technology, and Collaborative Product Lifecycle Management on Ship Maintenance and Modernization Cost Savings. https://doi.org/10.21236/ad1016676
50. Gammie, A., Sinha, S., & Bindal, S. (2012). User maintenance - the 'elephant in the room' of medical equipment. 7th International Conference on Appropriate Healthcare Technologies for Developing Countries, 74-74. https://doi.org/10.1049/cp.2012.1482
51. Gao, H. (2015). Medical Equipment Maintenance under Modernized Management. Proceedings of the 2015 International Conference on Management Science and Innovative Education. https://doi.org/10.2991/msie-15.2015.90
52. Gavurova, B., & Kubak, M. (2020). Efficiency Evaluation of Public Procurement of Medical Equipment. https://doi.org/10.20944/preprints202011.0392.v1
53. Gayler, B. (2008). Purchasing Capital Equipment. Radiology Business Practice, 144-162. https://doi.org/10.1016/b978-032304452-3.10011-4
54. Geraldine, S. L. (2018). Regulatory Affairs for Medical Device Clinical Trials in Asia Pacific. Handbook of Medical Device Regulatory Affairs in Asia, 107-128. https://doi.org/10.1201/9780429504396-13
55. Gill, P. (2016). Electrical Power Equipment Maintenance and Testing. https://doi.org/10.1201/9781420017557
56. Gilman, M., Hockenberry, J. M., Adams, E. K., Milstein, A. S., Wilson, I. B., & Becker, E. R. (2015). The Financial Effect of Value-Based Purchasing and the Hospital Readmissions Reduction Program on Safety-Net Hospitals in 2014. Annals of Internal Medicine, 163(6), 427-436. https://doi.org/10.7326/m14-2813
57. Glied, S. (2008). Health Care Financing, Efficiency, and Equity. https://doi.org/10.3386/w13881
58. Grenvik, A. (2001). Alternate Modes of Financing Health Care Technology. Annals of the Academy of Medicine, Singapore, 30(3), 222-225. https://doi.org/10.47102/annals-acadmedsg.v30n3p222
59. Grimes, S. L. (2018). CHAPTER 9: Medical Device Cybersecurity Risk Assessment. Medical Device Cybersecurity. https://doi.org/10.2345/9781570207136.ch09
60. Gupta, S. (2000a). Chapter-23 Hospital Equipment Repair and Maintenance. Hospital Stores Management, 137-140. https://doi.org/10.5005/jp/books/10360_23
61. Gupta, S. (2000b). Chapter-32 Imported Medical Equipment□Procurement Considerations. Hospital Stores Management, 199-202. https://doi.org/10.5005/jp/books/10360_32
62. Hafez, R. (2018). Nigeria Health Financing System Assessment. https://doi.org/10.1596/30174

63. Harjanti, H., Yuliansyah, N., & Widyaningrum, K. (2018). Daily Work Load Distribution to Increase Time Quality of Inpatients' Medical Record Document Procurement In X Hospital. Jurnal Medicoeticolegal dan Manajemen Rumah Sakit, 7(1). https://doi.org/10.18196/jmmr.7160
64. Harrington, S. E. (2009). Cost of Capital for Pharmaceutical, Biotechnology, and Medical Device Firms. https://doi.org/10.2139/ssrn.1512938
65. Hartz, S., & John, J. (2007). Public Health Policy Decisions on Medical Innovations: What Role Can Early Economic Evaluation Play?. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.1053701
66. Higson, G. R. (2002). Medical Device Safety. https://doi.org/10.1887/0750307684
67. Hill, D., & Scarola, K. (2004). Practical Maintenance of Digital Systems: Guidance to Maximize the Benefits of Digital Technology for the Maintenance of Digital Systems and Plant Equipment. https://doi.org/10.2172/835386
68. Hinrichs, S., & Colquhoun, P. (2008). Management of medical equipment in Romanian district hospital: current situation. 5th IET International Seminar on Appropriate Healthcare Technologies for Developing Countries (AHT 2008), 27-27. https://doi.org/10.1049/ic:20080595
69. Hofmann, B. M. (2020). Why ethics should be part of health technology assessment. The Ethical Challenges of Emerging Medical Technologies, 33-39. https://doi.org/10.4324/9781003074984-2
70. Hogaboam, L. (2000). Assessment of Technology Adoption Potential of Medical Devices: Case of Wearable Sensor Products for Pervasive Care in Neurosurgery and Orthopedics. https://doi.org/10.15760/etd.6093
71. Houria, Z. B., Masmoudi, M., Hanbali, A. A., Khatrouch, I., & Masmoudi, F. (2016). Quantitative techniques for medical equipment maintenance management. European J. of Industrial Engineering, 10(6), 703. https://doi.org/10.1504/ejie.2016.081017
72. Ife, O. A. U. I., Osun, & Nigeria (2017). Staphylococcus aureus Surface Colonization of Medical Equipment and Environment, Implication in Hospital- Community Epidemiology. Journal of Hospital & Medical Management, 03(01). https://doi.org/10.4172/2471-9781.100022
73. Iskandar, F., Santoso, F., Franzeska, A., Tasia, Y., & Mulyana, K. (2018). Mini Health Technology Assessment of Urban and Rural Health Care in Indonesia. Bali Medical Journal, 7(3). https://doi.org/10.15562/bmj.v7i3.932
74. Izet, M., Damir, C., Artan, P., Igor, K., & Haris, P. (2009). Quality Assessment of Medical Education and Use of Information Technology. Studies in Health Technology and Informatics. https://doi.org/10.3233/978-1-60750-044-5-898

75. Jacques, B., Tien, N. N., & Renaud, D. (1995). Technology Assessment in Medical and Health Care Informatics: A Clarification of the Concept. Studies in Health Technology and Informatics. https://doi.org/10.3233/978-1-60750-861-8-21
76. Jankovic, S. M., & Milivojevic, N. (2006). National-Level Purchasing of Expensive Drugs is Increasing Pressure on the Hospital Drug Budget. PharmacoEconomics, 24(8), 831-832. https://doi.org/10.2165/00019053-200624080-00008
77. Jiang, X., Pu, L., Wang, C., & Yang, D. O. (2016). Application of Extension Theory in the Assessment of Equipment Procurement Risk. Proceedings of the 6th International Conference on Electronic, Mechanical, Information and Management Society. https://doi.org/10.2991/emim-16.2016.264
78. Jordan, P. (2006). Standard IEC 62304 - Medical device software - Software lifecycle processes. IET Seminar on Software for Medical Devices, 2006, 41-47. https://doi.org/10.1049/ic:20060141
79. Joshi, P., Raghavan, S., & Joshi, M. (2016). Gaps in Knowledge and Awareness Related to Equipment Safety Among Nursing Personnel Working in Pediatric and Neonatal Medical-Surgical Icus at Tertiary Care Hospital. Journal of Multidisciplinary Research in Healthcare, 2(2), 125-131. https://doi.org/10.15415/jmrh.2016.22008
80. Kachieng'a, M. (2012). TECHNOLOGY MANAGEMENT IN THE PUBLIC HEALTH SECTOR: PROFESSIONAL VIEW FROM EQUIPMENT MAINTENANCE EXPERTS. The South African Journal of Industrial Engineering, 13(1). https://doi.org/10.7166/13-1-321
81. KimHeeSun, & 박균익 (2019). HTAi 의 INTEGRATE-Health Technology Assessment 프로젝트와 국내 시사점. The Journal of Health Technology Assessment, 7(1), 9-18. https://doi.org/10.34161/johta.2019.7.1.002
82. Kiselev, V., & Alexandrovna, Z. J. (2019). Is it Possible to Build a Profitable Maintenance Business in the Market of Heavy Medical Equipment in the B2G Segment?. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3389267
83. Kutor, J. K., Agede, P., & Ali, R. H. (2017). Maintenance Practice, Causes of Failure and Risk Assessment of Diagnostic Medical Equipment. Journal of Biomedical Engineering and Medical Devices, 02(01). https://doi.org/10.4172/2475-7586.1000123
84. L., T. J., & Ruud, V. D. L. (1995). Literature on Assessment of Information Technology and Medical KBS Evaluation: Studies and Methodologies. Studies in Health Technology and Informatics. https://doi.org/10.3233/978-1-60750-861-8-283
85. Lad, B. K., & Kulkarni, M. (2008). Integrated reliability and optimal maintenance schedule design: a Life Cycle Cost based approach. International Journal of Product Lifecycle Management, 3(1), 78. https://doi.org/10.1504/ijplm.2008.019971

86. Lakshmi, T. S., & Sahoo, D. (2012). Healthcare Financing Mechanisms in India: An Examination of Health Insurance. International Journal of Scientific Research, 2(1), 160-163. https://doi.org/10.15373/22778179/jan2013/54
87. Lambrechts, J. (2014). Information Lifecycle Governance (ILG): Maximise data value, reduce data growth, cost and risk. Australian Journal of Telecommunications and the Digital Economy, 2(3). https://doi.org/10.7790/ajtde.v2n3.46
88. Lee, P. (2000). Developing a practising balance medical equipment procurement for developing countries. IEE Seminar on Appropriate Medical Technology for Developing Countries, 2000, 12-12. https://doi.org/10.1049/ic:20000070
89. Lee, S. (2016). Patient Safety and Health Technology Assessment in Korea. The Journal of Health Technology Assessment, 4(1), 5-7. https://doi.org/10.34161/johta.2016.4.1.002
90. Levaggi, R., & Moretto, M. (2004). Investment in Hospital Care Technology Under Different Purchasing Rules: A Real Option Approach. https://doi.org/10.2139/ssrn.536002
91. Libres, A. C. (2017). Performance Assessment of Medical Technologists Overseeing Medical Technology Interns in Select Tertiary Hospitals. Asian Journal of Health, 7(1). https://doi.org/10.7828/ajoh.v6i1.930
92. Lo, M. (2004a). Benchmarking biomedical equipment maintenance in Hospital Authority (HA). 3rd IEE Seminar on Appropriate Medical Technology for Developing Countries, 13-13. https://doi.org/10.1049/ic.2004.0683
93. Lo, M. (2004b). Formulating equipment maintenance strategy in Hospital Authority (HA). 3rd IEE Seminar on Appropriate Medical Technology for Developing Countries, 14-14. https://doi.org/10.1049/ic.2004.0684
94. M, M., Z, A., N, N., & A, H. (2018). Frequency Analysis and Simulation of a Good Ground System to Protect Medical Electric Equipment Installed In Ilam Hospital. Journal of Electrical & Electronic Systems, 07(03). https://doi.org/10.4172/2332-0796.1000269
95. Maksim, T., & Georgy, K. (2017). Decision Support System for Medical Care Quality Assessment Based on Health Records Analysis in Russia. Studies in Health Technology and Informatics. https://doi.org/10.3233/978-1-61499-830-3-1371
96. Mankovich, N. (2006). Medical device security in hospital networks incorporating medical devices. IET Seminar on Software for Medical Devices, 2006, 49-63. https://doi.org/10.1049/ic:20060142
97. Marianne, M., & Thomas, N. (2016). Online Medical Device Use Prediction: Assessment of Accuracy. Studies in Health Technology and Informatics. https://doi.org/10.3233/978-1-61499-678-1-557
98. Masiye, F., & Chansa, C. (2019). Health Financing in Zambia. https://doi.org/10.1596/31786
99. Matt, D. T., Rauch, E., & Franzellin, V. M. (2015). An axiomatic design-based approach for the patient-value-oriented design of a sustainable Lean healthcare system. International Journal of Procurement Management, 8(1/2), 66. https://doi.org/10.1504/ijpm.2015.066288

100. Mboule, A. (2002). Standard lists of medical devices and a strategic maintenance plan: tools for appropriate medical technology. IEE Seminar on Appropriate Medical Technology for Developing Countries, 2002, 24-24. https://doi.org/10.1049/ic:20020059

101. McDowell, A. (2002). Tools and training: a practical approach towards improving healthcare equipment maintenance in The Gambia. IEE Seminar on Appropriate Medical Technology for Developing Countries, 2002, 9-9. https://doi.org/10.1049/ic:20020041

102. McQuoid-Mason, D. J. (2016). Public health officials and MECs should be held liable for harm caused to patients through incompetence, indifference, maladministration or negligence regarding the availability of hospital equipment. South African Medical Journal, 106(7), 681. https://doi.org/10.7196/samj.2016.v106i7.10722

103. Moore, M. (2011). Phase II - Procurement of State of the Art Research Equipment to Support Faculty Members with the RNA Therapeutics Institute, a component of the Advanced Therapeutics Cluster at the University of Massachusetts Medical School. https://doi.org/10.2172/1037882

104. Mueller, D. B., Govender, M., & Basu, D. (2011). Health technology assessment in South Africa - future promise. South African Medical Journal, 101(5), 286. https://doi.org/10.7196/samj.4867

105. Muhia, J., Waithera, L., & Songole, R. (2017). Factors Affecting the Procurement of Pharmaceutical Drugs: A Case Study of Narok County Referral Hospital, Kenya. Medical & Clinical Reviews, 03(04). https://doi.org/10.21767/2471-299x.1000061

106. Murphy, K., & Topel, R. (2016). Human Capital Investment, Inequality and Economic Growth. https://doi.org/10.3386/w21841

107. Myerson, P. (2018). History and Importance of Procurement and Purchasing in Adding Value to an Organization. Lean Demand-Driven Procurement, 15-26. https://doi.org/10.4324/9780429442582-2

108. Noori, J., Rezaee, R., Mahmoudi, S., & Masaeli, R. (2020). Outcomes of public procurement in technology development of medical devices: A narrative review. International Archives of Health Sciences, 7(3), 113. https://doi.org/10.4103/iahs.iahs_75_19

109. Olaiya, S. T. (1999). Selection of Equipment Service Option, Estimation of Equipment Maintenance Costs, and Comparative Costs Analysis, Brooke Army Medical Center, Fort Sam Houston, Texas. https://doi.org/10.21236/ada420753

110. Olorunniwo, F. O. (1992). Life-cycle Cost Policy when Equipment Maintenance Is Imperfect. International Journal of Quality & Reliability Management, 9(6). https://doi.org/10.1108/02656719210018624

111. Omelyanovskiy, V. V., Gorkavenko, F. V., Saybel, Y. S., & Khachatryan, G. R. (2019). Health Technology Assessment System in Sweden. Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор), 16-23. https://doi.org/10.31556/2219-0678.2019.36.2.016-023

112. Palas, M. J. U., Ashraf, M., & Ray, P. K. (2017). Financing Universal Health Coverage: A Systematic Review. The International Technology Management Review, 6(4), 133. https://doi.org/10.2991/itmr.2017.6.4.2

113. Park, C. Y. (2018). Data-Linking Infrastructure for the Health Technology Assessment. The Journal of Health Technology Assessment, 6(2), 81-87. https://doi.org/10.34161/johta.2018.6.2.001

114. Pathirana, N., Dharmarathne, G. S. K., & Dissanayake, D. M. J. B. (2019a). Assessing the Physical and Financial Progress of the Medical Equipment Procurement Process – A Study at the Regional Directorate of Health Services (RDHS) in Gampaha, Sri Lanka. International Journal of Scientific and Research Publications (IJSRP), 9(9), p9338. https://doi.org/10.29322/ijsrp.9.09.2019.p9338

115. Pathirana, N., Dharmarathne, G. S. K., & Dissanayake, D. M. J. B. (2019b). Factors Affecting the Timeliness of the Medical Equipment Procurement Process – A study at the Regional Directorate of Health Services (RDHS) in Gampaha, Sri Lanka. International Journal of Scientific and Research Publications (IJSRP), 9(9), p9337. https://doi.org/10.29322/ijsrp.9.09.2019.p9337

116. Peng, K. (2012). Equipment Management in the Post-Maintenance Era. https://doi.org/10.1201/b11916

117. Phillips, V. L. (2015). Value-Based Purchasing in Healthcare: How the US Government is Securing Quality Improvement in Care in the United States. Review of Public Administration and Management, 03(01). https://doi.org/10.4172/2315-7844.1000158

118. Piepenbrink, J. (2003). Medical Device Safety—The Regulation of Medical Devices for Public Health and Safety. Biomedical Instrumentation & Technology, 37(1), 71-71. https://doi.org/10.2345/0899-8205(2003)37[71:mdsrom]2.0.co;2

119. Pinto, R., Masaki, E., & Harimurti, P. (2016). Indonesia Health Financing System Assessment. https://doi.org/10.1596/26311

120. Prier, E., McCue, C., & Behara, R. (2010). The value of certification in public procurement: The birth of a profession?. Journal of Public Procurement, 10(4), 512-540. https://doi.org/10.1108/jopp-10-04-2010-b002

121. Rajoriya, B. (2018). Clinical/Support Service Equipment Management and Medical Audit. Hospital and Healthcare Accreditation (As Per the Guidelines of NABH, NABL, JCI), 177-177. https://doi.org/10.5005/jp/books/14251_33

122. Ramakrishna, S., & Babu, P. S. (2017). Procurement and Supply of Anti Snake Venom as a Determinant of Snake Bite Management Outcome at a Government Medical College Hospital in Karnataka. International Journal of Medicine and Public Health, 7(1), 47-50. https://doi.org/10.5530/ijmedph.2017.1.8

123. Robbins, P. (2007). Chasing the Holy Grail? - Effective 21st century equipment maintenance. IET Seminar on Medical Device Management - More than Maintenance, 25-36. https://doi.org/10.1049/ic:20070518

124. Romera, B. M., & Caranta, R. (2017). EU Public Procurement Law: Purchasing Beyond Price in the Age of Climate Change. European Procurement & Public Private Partnership Law Review, 12(3), 281-292. https://doi.org/10.21552/epppl/2017/3/10

125. Rovira, L. (2018). 04 / A new medical device that Converts a LaryngoscopE into a low-cost VideolaryngoscopE Reusable. (C.LE.VE.R.scope). https://doi.org/10.26226/morressier.5aeb0acb07b0d6001a79aa52

126. Sakamaki, H. (2020). Pricing and Reimbursement Systems of Drugs and Medical Devices and Health Technology Assessment in Japan. World Scientific Series in Global Health Economics and Public Policy, 275-289. https://doi.org/10.1142/9789813236141_0020

127. Salimgali, G., & Omirbayeva, B. (2020). Proposal to improve the financing of infectious diseases providers within the framework of the guaranteed amount of free medical care and in the mandatory social health insurance system. JOURNAL OF HEALTH DEVELOPMENT, special(36), 61-68. https://doi.org/10.32921/2225-9929-2020-36-61-68

128. Scandizzo, P. L. (2004). Financing Technology: An Assessment of Theory and Practice. https://doi.org/10.2139/ssrn.486823

129. Schieber, G., Cashin, C., Saleh, K., & Lavado, R. (2012). Ghana's Health Financing: A Performance Assessment. Health Financing in Ghana, 33-90. https://doi.org/10.1596/9780821395660_ch02

130. Sharma, N. (2017). Study About Awareness and Practices of Health Care Waste Management among Medical Practitioners and Hospital Staff in a Medical College Hospital, Jabalpur. Journal of Medical Science And clinical Research, 05(03), 18890-18895. https://doi.org/10.18535/jmscr/v5i3.96

131. Silke, S., & Marcel, V. (2013). The PHM-Ethics Methodology: Interdisciplinary Technology Assessment of Personal Health Monitoring. Studies in Health Technology and Informatics. https://doi.org/10.3233/978-1-61499-256-1-13

132. Siminoff, L., & Traino, H. (2009). Improving donation outcomes: hospital development and the Rapid Assessment of Hospital Procurement Barriers in Donation. Progress in Transplantation, 19(2), 180-187. https://doi.org/10.7182/prtr.19.2.338575875ug02252

133. Simon, H., Werner, W., Udo, A., Ralf, S., & Joachim, D. (2000). Structured Clinical Documentation for the Assessment of Medical Care. Studies in Health Technology and Informatics. https://doi.org/10.3233/978-1-60750-921-9-480

134. SİMSİR, İ., & ALTINDİŞ, S. (2019). Could Value-Based Purchasing Approach Be Used in Assessment of Healthcare Delivery Outputs?. Konuralp Tıp Dergisi, 11(3), 475-481. https://doi.org/10.18521/ktd.591897

135. Steward, D., Saur, G., Penev, M., & Ramsden, T. (2009). Lifecycle Cost Analysis of Hydrogen Versus Other Technologies for Electrical Energy Storage. https://doi.org/10.2172/968186

136. Suharsh, D., Bhaskar, D., Prabhu, D., & Rakesh, D. (2016). Application of Pert in Reduction of Equipment Procurement Time in a Tertiary Care Teaching Hospital. IOSR Journal of Dental and Medical Sciences, 15(10), 102-104. https://doi.org/10.9790/0853-151004102104

137. Symington, S., Polk, W., & Souppaya, M. (2020). Trusted Internet of Things (IoT) Device Network-Layer Onboarding and Lifecycle Management (Draft). https://doi.org/10.6028/nist.cswp.09082020-draft

138. Tabarov, A., Zholdasov, Z., & Esbatyrova, L. (2020). Improving the system for Health technology assessment in Kazakhstan for healthcare decision-making. JOURNAL OF HEALTH DEVELOPMENT, special(36), 18-24. https://doi.org/10.32921/2225-9929-2020-36-18-24

139. Tanenbaum, S. J. (2016). What Is the Value of Value-Based Purchasing?. Journal of Health Politics, Policy and Law, 41(5), 1033-1045. https://doi.org/10.1215/03616878-3632254

140. Tanimoto, K., Matsushita, M., & Tatano, H. (2005). Lifecycle Cost Evaluation of Maintenance Policy—The Case of the Water Transmission System in Kobe. Systems and Human Science, 147-158. https://doi.org/10.1016/b978-044451813-2/50013-0

141. Teo, H. S., & Cain, J. S. (2018). Myanmar Health Financing System Assessment. https://doi.org/10.1596/31007

142. Teptsova, T. S., & Lemeshko, V. A. (2018). Health Technology Assessment in Scotland. Medical Technologies. Assessment and Choice, 32(2), 34-41. https://doi.org/10.31556/2219-0678.2018.32.2.034-041

143. Tsarouhas, P. H. (2015). Evaluation of maintenance management through the overall equipment effectiveness of a yogurt production line in a medium-sized Italian company. International Journal of Productivity and Quality Management, 16(3), 298. https://doi.org/10.1504/ijpqm.2015.071504

144. Vesal, S., Abtahi, M., Alikhani, P., Ganji, H., & Naghdi, B. (2013). Preventive maintenance of medical equipment in Alzahra Hospital, Isfahan, Iran 2013. International Journal of Health System and Disaster Management, 1(4), 217. https://doi.org/10.4103/2347-9019.130738

145. Visconti, R. M. (2014). PPP versus Traditional Healthcare Procurement in Italy: Assessing Value for Money with PESTLE and SWOT Analysis. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.2422450

146. W., J. R., & Konstantinos, K. (2017). Cybersecurity and the Medical Device Product Development Lifecycle. Studies in Health Technology and Informatics. https://doi.org/10.3233/978-1-61499-781-8-76

147. Wagstaff, A. (2001). Measuring Equity in Health Care Financing: Reflections on (and Alternatives to) the World Health Organization's Fairness of Financing Index. https://doi.org/10.1596/1813-9450-2550

148. Wang, C., & Yang, K. (2015). An Applied Research of Equipment Procurement Bidding Based on Fuzzy Syntheticism—A Case of Purchasing of a Certain Type of Command Vehicle Equipment as Example. Advances in Intelligent Systems Research. https://doi.org/10.2991/isrme-15.2015.290
149. Wang, T. (2016). A Novel Medical Equipment Maintenance System Design and Implementation. Advanced Science and Technology Letters, 375-379. https://doi.org/10.14257/astl.2016.139.75
150. Zhang, J. (2015). Medical Equipment Maintenance under Modern Management. Proceedings of the 2015 International Conference on Management Science and Innovative Education. https://doi.org/10.2991/msie-15.2015.88
151. Tonoyan, A., Dada, O. & Ayivi-Donkor, S.S. (2024). Advances in Supply Chain Resilience: Predictive Models for Vendor Risk Assessment and Procurement Cost Optimization. International Journal of Social Sciences and Management Research, 10(11), pp.525–551. DOI: 10.56201/ijssmr.v10.no11.2024.pg.525.551.
152. Okojie, J. S., Filani, O. M., Ihwughwavwe, S. I., & Sakyi, J. K. (2020). Sustainable procurement practices: ESG-integrated supply chain models for corporate responsibility and environmental performance. IRE Journals, 4(2).
153. Okoruwa, P. O., Babatope, O. M., Akokodaripon, D. A., & Akinleye, O. K. (2024). Developing integrated digital platforms for enhancing transparency in procurement and supply chain management. International Journal of Multidisciplinary Research and Growth Evaluation, 5(6), 1719–1729.
154. Okoruwa, P. O., Babatope, O. M., Akokodaripon, D. A., & Akinleye, O. K. (2025). Digital procurement transformation approaches for strengthening efficiency in global supply chain management. International Journal of Multidisciplinary Research and Growth Evaluation, 6(5), 975–985. Folder 2 — Research Publications (gbemisola.falegan@gmail.com)
155. Aifuwa, S. E., Oshoba, T. O., Ogbuefi, E., Ike, P. N., Nnabueze, S. B., & Olatunde-Thorpe, J. (2020). Predictive analytics models enhancing supply chain demand forecasting accuracy and reducing inventory management inefficiencies. International Journal of Multidisciplinary Research and Growth Evaluation, 1(3), 171–181. https://doi.org/10.54660/.IJMRGE.2020.1.3.171-181
156. Akinleye, O. K., & Adeyoyin, O. (2022). Supplier relationship management framework for achieving strategic procurement objectives. Gyanshauryam, International Scientific Refereed Research Journal, 5(4), 565–598. https://doi.org/10.32628/GISRRJ225430 Journal Article (CSEIT)
157. Agbabiaka, J., Okonkwo, C.S., Ogunwole, O., Mayo, W. & Okeke, O.T. (2019). Supply Chain Risk Management Model for EPC and Gas Processing Projects. IRE Journals, 3(2), pp.968–980. DOI: 10.64388/IREV3I2-1713124.
158. Ike, P. N., Ogbuefi, E., Nnabueze, S. B., Olatunde-Thorpe, J., Aifuwa, S. E., Oshoba, T. O., & Akokodaripon, D. (2021). Supplier relationship management strategies fostering innovation,

collaboration, and resilience in global supply chain ecosystems. International Journal of Multidisciplinary Evolutionary Research, 2(2), 52–62. https://doi.org/10.54660/IJMER.2021.2.2.52-62

159. Ike, P. N., Aifuwa, S. E., Nnabueze, S. B., Olatunde-Thorpe, J., Ogbuefi, E., Oshoba, T. O., & Akokodaripon, D. (2024). Utilizing nanomaterials in healthcare supply chain management for improved drug delivery systems. International Journal of Advanced Multidisciplinary Research and Studies, 4(4), 1567–1572. https://doi.org/10.62225/2583049X.2024.4.4.5154

160. Akinleye, O. K. (2023). Regulatory compliance and supplier risk assessment frameworks in international pharmaceutical procurement. International Journal of Advanced Multidisciplinary Research and Studies, 3(6), 2194–2204.

161. Okonkwo, C.S., Ogunwole, O., Okeke, O.T. & Mayo, W (2019). Conceptual Framework for Cost Reduction Through Contract Negotiation and Vendor Governance. IRE Journals, 2(9), pp.468–482. DOI: 10.64388/IREV2I9-1713121.

162. Mbonu, I.S., Iwuanyanwu, U., Aliliele, C. & Uzoka, E (2020). A Conceptual Framework for Agile Supply Chain Digital Transformation with Embedded IT Risk and ISO Compliance Controls. Iconic Research and Engineering Journals, 3(11), pp.566–593. DOI: 10.64388/IREV3I11-1714916.

163. Oparah, O. S., Ezeh, F. E., Olatunji, G. I., & Ajayi, O. O (2021). AI-based risk stratification framework for large-scale public health emergency preparedness and response planning. International Journal of Scientific Research in Computer Science, Engineering and Information Technology, 7(1), 332-366.

164. Okonkwo, C.S., Mayo, W. & Okeke, O.T (2023). Conceptual Model for Asset Lifecycle Management and Inventory Visibility. International Journal of Scientific Research in Computer Science, Engineering and Information Technology, 10(1), pp.809–824. DOI: 10.32628/CSEIT2391568.

165. Akin-Oluyomi, O. T., Atima, M. E., & Akinleye, O. K (2023a). Regulatory compliance and supplier risk assessment frameworks in international pharmaceutical procurement. International Journal of Advanced Multidisciplinary Research and Studies, 3(6), 2194–2204.

166. Akin-Oluyomi, O. T., Okoruwa, P. O., Babatope, O. M., & Akokodaripon, D. A (2023b). Evaluating supplier sustainability metrics through data-driven procurement and supply chain frameworks. International Journal of Advanced Multidisciplinary Research and Studies, 3(6), 2213–2223.

167. Akinlolu, V. S., Omaghomi, T. T., & Fapohunda, M (2024). A data-driven framework for improving health facility preparedness and disaster risk mitigation in urban hospitals. International Journal of Advanced Multidisciplinary Research and Studies, 4.

168. Oparah, O. S., Ezeh, F. E., Olatunji, G. I., & Ajayi, O. O (2024). Framework for integrating climate data and health outcomes to improve mortality risk prediction systems. International Journal of Scientific Research in Computer Science, Engineering and Information Technology, 10(2), 1128-1150.

169. Olodo, A., Akanbi, O., & Adenuga, O (2026). Conceptualizing a lean-standardized predictive maintenance framework for high-vacuum deposition equipment. International Journal of Engineering and Modern Technology, 12(3), 295–322. https://doi.org/10.56201/ijemt.vol.12.no3.2026.pg295.322

170. Atakpa, M.I., Abolaji, T.O. & Abetoh, N.F (2024a). Statistical Time-Series Models for Long-Range Public Health Trend Forecasting: A Review and Conceptual Framework. International Journal of Scientific Research in Computer Science, Engineering and Information Technology, 10(6), pp.2748–2780. DOI: 10.32628/CSEIT2410792.

171. Atakpa, M.I., Abolaji, T. & Abetoh, N.F (2026). An Integrated Big Data Framework for Healthcare Financial Analytics: Fraud Detection and Cost Optimization. Iconic Research and Engineering Journals, 9(12). DOI: 10.64388/IREV9I12-1719047.

172. Okonkwo, C.S., Ogunwole, O., Mayo, W. & Okeke, O.T (2021). Framework for Regulatory-Compliant Procurement in High-Risk Energy Environments. International Journal of Multidisciplinary Research and Growth Evaluation, 2(6), pp.595–605. DOI: 10.54660/IJMRGE.2021.2.6.595-605.

173. Ogbete, J.C., Aminu-Ibrahim, A. & Ambali, K.B (2021). Risk Managed Construction Strategies for Complex and Highly Regulated Healthcare Facility Developments. International Journal of Scientific Research in Computer Science, Engineering and Information Technology, 7(5), pp.362-392. DOI: 10.32628/CSEIT217561

174. Mbonu, I.S., Aliliele, C., Iwuanyanwu, U. & Uzoka, E (2021). A Conceptual Framework for Risk Based Business Intelligence Architecture in Financial Technology Platforms. International Journal of Multidisciplinary Research and Growth Evaluation, 2(6), pp.731–746. DOI: 10.54660/IJMRGE.2021.2.6.731-746.

175. Aneke, O.B. & Adesemoye, A.C (2021). Reframing Trade and Import Compliance: A Conceptual Model for Risk-Based Interdiction of Illicit Medical Products. International Journal of Scientific Research in Science and Technology, 8(6), pp.1226–1248.

176. Filani, O. M., Nnabueze, S. B., Ike, P. N., & Wedraogo, L (2022). Real-time risk assessment dashboards using machine learning in hospital supply chain management systems. International Journal of Multidisciplinary Evolutionary Research, 3(1), 65–76. https://doi.org/10.54660/IJMER.2022.3.1.65-76

177. Falegan, O. C., & Aniebonam, S. O (2022). Conceptual framework for lifecycle risk assessment in offshore produced water management. Gyanshauryam, International Scientific Refereed Research Journal, 5(5), 322–345.

178. Aliliele, C., Mbonu, I.S. & Iwuanyanwu, U (2023a). A Conceptual Framework for Continuous Cloud Misconfiguration Monitoring and Enterprise Risk Mitigation Strategies. International Journal of Scientific Research in Computer Science, Engineering and Information Technology, 9(10), pp.373–394. DOI: 10.32628/CSEIT2361071.

179. Aliliele, C., Mbonu, I.S. & Iwuanyanwu, U (2023b). A Review of API Governance and Risk Prioritization Frameworks in Modern Financial Institutions. International Journal of Scientific

Research in Computer Science, Engineering and Information Technology, 9(10), pp.395–433. DOI: 10.32628/CSEIT2361072.

180. Okonkwo, C.S., Agbabiaka, J., Mayo, W. & Okeke, O.T (2024a). Conceptual Framework for Digital Supply Chain Governance in Energy and Infrastructure Sectors. Gyanshauryam, International Scientific Refereed Research Journal, 7(4), pp.335–356. DOI: 10.32628/GISRRJ247423.
181. Okonkwo, C.S., Agbabiaka, J., Mayo, W. & Okeke, O.T (2024b). Review of Digital Supply Chain Models for Cost Control and Operational Continuity. International Journal of Advanced Multidisciplinary Research and Studies, 4(6), pp.2836–2846. DOI: 10.62225/2583049X.2024.4.6.5496
182. Eboh, E.E. & Aliliele, C (2024). AI-Driven Data Analytics Framework for Risk Assessment and Detection of Venture Capital and Private Equity Investment Fraud in U.S. Capital Markets. International Journal of Scientific Research in Computer Science, Engineering and Information Technology, 10(6), pp.2624–2665. DOI: 10.32628/CSEIT2410787.
183. Nnaji, N., & Akinlolu, V. S (2024). Strengthening medical information flow through digital operations models for modern mental health care. Gyanshauryam, International Scientific Refereed Research Journal (GISRRJ), 7.
184. Falegan, O. C., & Aniebonam, S. O (2024). Decentralized produced water treatment systems for remote energy assets: A conceptual design framework. International Journal of Scientific Research in Computer Science, Engineering and Information Technology, 10(3), 1133–1151. https://doi.org/10.32628/IJSRCSEIT
185. Akinlade, O. F., Filani, O. M., & Nwachukwu, P. S (2024). Automation and digital twins framework reducing procurement errors and turnaround time. International Journal of Scientific Research in Humanities and Social Sciences, 1(1), 197-216.
186. Ekwunife, D. I., PRECIOUS, O. T., RASUL, O. A., AKINLADE, O. F., NWOKORO, T. O., & IKPE, V. I (2024). Using blockchain technology to maximize supply chain and logistics management in North America. Int. J. Sci. Res. Arch, 12(2), 854-863.
187. Okafor, C. M., Osuji, V. C., & Dako, O. F (2024). Harmonizing risk governance, technology infrastructure, and compliance frameworks for future-ready banking systems. International Journal of Scientific Research in Humanities and Social Sciences, 1(1), 316-337.
188. Akinola, A. S., Adesanya, O. S., Okafor, C. M., & Dako, O. F (2024). Value-chain automation in beverage logistics: Throughput, capacity, and cost avoidance via queueing models. International Journal of Scientific Research in Computer Science, Engineering and Information Technology, 10(4), 1112–1132.
189. Okonkwo, C.S., Agbabiaka, J., Okeke, O.T. & Mayo, W (2025). Framework for National-Scale Supply Chain Optimization Through Integrated IT and Procurement Systems. Gulf Journal of Advance Business Research, 3(12), pp.1610–1625. DOI: 10.51594/gjabr.v3i12.189.

190. Aminu-Ibrahim, A., Ogbete, J.C. & Iwuanyanwu, O.C (2025a). Sustainable Healthcare Infrastructure Performance Metrics for Long-Term Asset Management and Value Creation. International Journal of Scientific Research in Computer Science, Engineering and Information Technology, 11(4), pp.566–601. DOI: 10.32628/CSEIT251116277.

191. Aminu-Ibrahim, A.Y., Ogbete, J.C. & Iwuanyanwu, O.C (2025b). Cost Control and Financial Accountability Frameworks for National Healthcare Construction Programs. International Journal of Advanced Multidisciplinary Research and Studies, 5(6), pp.1970–1990. DOI: 10.62225/2583049X.2025.5.6.5700.

192. Tonoyan, A., Dada, O. & Ayivi-Donkor, S.S (2025). A Conceptual Model for Real-Time Route Optimization: Algorithmic Pathways to Delivery Profitability and Logistics Cost Reduction. World Journal of Innovation and Modern Technology, 9(12), pp.308–364. DOI: 10.56201/wjimt.v9.no12.2025.pg308.364.

193. Fapohunda, M., Akinlolu, V. S., Omaghomi, T. T., & Efetobore, M (2025a). A policy and research framework for strengthening emergency response coordination across hospital units. International Journal of Health and Pharmaceutical Research, 10(12), 34–51.

194. Fapohunda, M., Omaghomi, T. T., Akinlolu, V. S., & Atima, M. E (2025b). A policy-oriented framework for strengthening behavioral health crisis response systems in multi-hospital networks. International Journal of Health and Pharmaceutical Research, 10(12), 34–51.

195. Uduokhai, D. O., Nwafor, M. I., Sanusi, A. N., & Garba, B. M. P (2025). Predictive framework for optimizing maintenance schedules in aging public infrastructure systems. Global Journal of Engineering and Technology Review, 1(3), 142-152.

196. Nnaji, N., & Akinlolu, V. S (2026). Integrating health informatics, analytics, and digital operations to improve healthcare performance, data security, and mental health care. International Medical Science Research Journal, 6(1), 40–68.

197. Sharon, A. V., & Rihel, K (2026). Nicotine use and vape waste in Connecticut: A dual public health and environmental policy framework for prevention, harm reduction and sustainable disposal. International Journal of Scientific Research and Modern Technology (IJSRMT).

198. Unamma, U.M-L., Okwesa, I.J., Iwuanyanwu, U. & Ajiga, D (2018a). An Offline-First Design Framework for Digital Learning in Low-Connectivity Environments. Iconic Research and Engineering Journals, 2(3), pp.192–211. DOI: 10.64388/IREV2I3-1722627.

199. Unamma, U.M-L., Ashore-Onisemo, F., Iwuanyanwu, U. & Okwesa, I.J (2018b). Digital Inclusion and Workforce-Readiness Interventions in Emerging Economies: A Review. International Journal of Scientific Research in Computer Science, Engineering and Information Technology, 3(8), pp.475–493. DOI: 10.32628/CSEIT12283141.

200. Ashore-Onisemo, F., Okwesa, I.J. & Unamma, U.M-L (2020). Machine Learning for Credit Risk and Default Prediction in Retail and SME Lending: A Systematic Review. International Journal of Scientific Research in Computer Science, Engineering and Information Technology, 6(6), pp.477–503. DOI: 10.32628/CSEIT2066446.

201. Atakpa, M.I. & Abolaji, T (2020). Data-Driven Health Equity: A Proposed Framework for Analytics-Based Health Needs Assessment in Underserved Communities. IRE Journals, Iconic Research and Engineering Journals, 4(5), pp.410–432. DOI: 10.64388/IREV4I5-1718410.

202. Unamma, U.M-L (2022). A Machine-Learning-Augmented Framework for Financial Modeling, Valuation, and Scenario Analysis under Uncertainty. International Journal of Scientific Research in Science and Technology, 9(6), pp.853–893. DOI: 10.32628/IJSRST25122131.

203. Abetoh, N.F. & Atakpa, M.I (2022). Predictive Analytics for Fraud Detection in Donor-Funded Health Program Audits: A Conceptual Framework for Sub-Saharan African Contexts. International Journal of Multidisciplinary Research and Growth Evaluation, 3(6), pp.1036–1054. DOI: 10.54660/.IJMRGE.2022.3.6.1036-1054.

204. Atakpa, M.I. & Fobellah, A.N (2023a). Anomaly Detection in Financial Time-Series Data: A Conceptual Model for Healthcare and Banking Applications. International Journal of Scientific Research in Computer Science, Engineering and Information Technology, 9(2), pp.967–997. DOI: 10.32628/CSEIT2342441.

205. Atakpa, M.I., Abolaji, T.O. & Akeju, B (2023b). A Review of Natural Language Processing for Social Media-Based Public Health Surveillance and Analytics. International Journal of Scientific Research in Computer Science, Engineering and Information Technology, 9(6), pp.1030–1060. DOI: 10.32628/CSEIT23906783.

206. Abetoh, N.F. & Atakpa, M.I (2024). Audit Analytics in Healthcare Financial Oversight: Leveraging Data Science to Strengthen Accountability in Multilateral Grant Ecosystems. International Journal of Scientific Research in Computer Science, Engineering and Information Technology, 10(6), pp.2710–2747. DOI: 10.32628/CSEIT2410791.

207. Atakpa, M.I., Abetoh, N.F. & Akeju, B (2024b). Advances in Artificial Intelligence for Healthcare Payment Fraud Detection: A Review of NHS Applications. International Journal of Scientific Research in Computer Science, Engineering and Information Technology, 10(4), pp.1161–1194. DOI: 10.32628/CSEIT26123240.

208. Okonkwo, C.S., Ogunwole, O. & Okeke, O.T (2018). Framework for Strategic Procurement Optimization in Oil and Gas Operations. IRE Journals, 1(7), pp.153–168. DOI: 10.64388/IREV1I7-1713119.

209. Mbonu, I.S., Aliliele, C., Iwuanyanwu, U. & Oluoha, O.M (2018). A Conceptual Framework for Legal and Ethical Risk Modeling in Enterprise Data Protection Governance Systems. Iconic Research and Engineering Journals, 2(2), pp.207–226. DOI: 10.64388/IREV2I2-1714911.

210. Adeyelu, O.O (2018). A Predictive Compliance Monitoring Framework for Detecting Systemic Safety Risks Through Aviation Consumer Complaint Data. Iconic Research and Engineering Journals, 1(8), pp.250–276. DOI: 10.64388/IREV1I8-1718478.